<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer - Kim, S - 2023 | Cochrane Library</title> <meta content="Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer - Kim, S - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012817.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer - Kim, S - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012817.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012817.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer" name="citation_title"/> <meta content="Sunghyun Kim&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Jee Hyun Kong&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="YoHan Lee" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Jun Young Lee" name="citation_author"/> <meta content="Tae Wook Kang" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Tae Hoon Kong" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Myung Ha Kim" name="citation_author"/> <meta content="Yonsei University Wonju College of Medicine" name="citation_author_institution"/> <meta content="Sei Hwan You" name="citation_author"/> <meta content="ys3259@yonsei.ac.kr" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD012817.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/03/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012817.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012817.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012817.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Prostatectomy [adverse effects]; *Prostatic Neoplasms [pathology]; Systematic Reviews as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012817.pub2&amp;doi=10.1002/14651858.CD012817.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012817\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012817\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ko","ms","hr","fr","zh_HANS","zh_HANT","th","fa","id","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012817.pub2",title:"Dose\\u2010escalated radiotherapy for clinically localized and locally advanced prostate cancer",firstPublishedDate:"Mar 8, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012817.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012817.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012817.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012817.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012817.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012817.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012817.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012817.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012817.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012817.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1951 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012817.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/appendices#CD012817-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/supinfo/CD012817StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/supinfo/CD012817StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work."><a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#CD012817-cr-0004">Sunghyun Kim</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work."><a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#CD012817-cr-0005">Jee Hyun Kong</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#CD012817-cr-0006">YoHan Lee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#CD012817-cr-0007">Jun Young Lee</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#CD012817-cr-0008">Tae Wook Kang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#CD012817-cr-0009">Tae Hoon Kong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#CD012817-cr-0010">Myung Ha Kim</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information#CD012817-cr-0011"><i class="icon corresponding-author fa fa-envelope"></i>Sei Hwan You</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information/en#CD012817-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 March 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012817.pub2">https://doi.org/10.1002/14651858.CD012817.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012817-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012817-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012817-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012817-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012817-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012817-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012817-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012817-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012817-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012817-abs-0001" lang="en"> <section id="CD012817-sec-0001"> <h3 class="title" id="CD012817-sec-0001">Background</h3> <p>Treatments for clinically localized prostate cancer include radical prostatectomy, external beam radiation therapy, brachytherapy, active surveillance, hormonal therapy, and watchful waiting. For external beam radiation therapy, oncological outcomes may be expected to improve as the dose of radiotherapy (RT) increases. However, radiation‐mediated side effects on surrounding critical organs may also increase. </p> </section> <section id="CD012817-sec-0002"> <h3 class="title" id="CD012817-sec-0002">Objectives</h3> <p>To assess the effects of dose‐escalated RT in comparison with conventional dose RT for curative treatment of clinically localized and locally advanced prostate cancer. </p> </section> <section id="CD012817-sec-0003"> <h3 class="title" id="CD012817-sec-0003">Search methods</h3> <p>We performed a comprehensive search using multiple databases including trial registries and other sources of grey literature, up until 20 July 2022. We applied no restrictions on publication language or status. </p> </section> <section id="CD012817-sec-0004"> <h3 class="title" id="CD012817-sec-0004">Selection criteria</h3> <p>We included parallel‐arm randomized controlled trials (RCTs) of definitive RT in men with clinically localized and locally advanced prostate adenocarcinoma. RT was dose‐escalated RT (equivalent dose in 2 Gy [EQD<sub>2</sub>] ≥ 74 Gy, lesser than 2.5 Gy per fraction) versus conventional RT (EQD<sub>2</sub> &lt; 74 Gy, 1.8 Gy or 2.0 Gy per fraction). Two review authors independently classified studies for inclusion or exclusion. </p> </section> <section id="CD012817-sec-0005"> <h3 class="title" id="CD012817-sec-0005">Data collection and analysis</h3> <p>Two review authors independently abstracted data from the included studies. We performed statistical analyses by using a random‐effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We used GRADE guidance to rate the certainty of the evidence of RCTs. </p> </section> <section id="CD012817-sec-0006"> <h3 class="title" id="CD012817-sec-0006">Main results</h3> <p>We included nine studies with 5437 men in an analysis comparing dose‐escalated RT versus conventional dose RT for the treatment of prostate cancer. The mean participant age ranged from 67 to 71 years. Almost all men had localized prostate cancer (cT1‐3N0M0). </p> <p><b>Primary outcomes</b> </p> <p>Dose‐escalated RT probably results in little to no difference in time to death from prostate cancer (hazard ratio [HR] 0.83, 95% CI 0.66 to 1.04; I<sup>2</sup> = 0%; 8 studies; 5231 participants; moderate‐certainty evidence). Assuming a risk of death from prostate cancer of 4 per 1000 at 10 years in the conventional dose RT group, this corresponds to 1 fewer men per 1000 (1 fewer to 0 more) dying of prostate cancer in the dose‐escalated RT group. </p> <p>Dose‐escalated RT probably results in little to no difference in severe RT toxicity of grade 3 or higher late gastrointestinal (GI) toxicity (RR 1.72, 95% CI 1.32 to 2.25; I<sup>2</sup> = 0%; 8 studies; 4992 participants; moderate‐certainty evidence); 23 more men per 1000 (10 more to 40 more) in the dose‐escalated RT group assuming severe late GI toxicity as 32 per 1000 in the conventional dose RT group. Dose‐escalated RT probably results in little to no difference in severe late genitourinary (GU) toxicity (RR 1.25, 95% CI 0.95 to 1.63; I<sup>2</sup> = 0%; 8 studies; 4962 participants; moderate‐certainty evidence); 9 more men per 1000 (2 fewer to 23 more) in the dose‐escalated RT group assuming severe late GU toxicity as 37 per 1000 in the conventional dose RT group. </p> <p><b>Secondary outcomes</b> </p> <p>Dose‐escalated RT probably results in little to no difference in time to death from any cause (HR 0.98, 95% CI 0.89 to 1.09; I<sup>2</sup> = 0%; 9 studies; 5437 participants; moderate‐certainty evidence). Assuming a risk of death from any cause of 101 per 1000 at 10 years in the conventional dose RT group, this corresponds to 2 fewer men per 1000 (11 fewer to 9 more) in the dose‐escalated RT group dying of any cause. </p> <p>Dose‐escalated RT probably results in little to no difference in time to distant metastasis (HR 0.83, 95% CI 0.57 to 1.22; I<sup>2</sup> = 45%; 7 studies; 3499 participants; moderate‐certainty evidence). Assuming a risk of distant metastasis of 29 per 1000 in the conventional dose RT group at 10 years, this corresponds to 5 fewer men per 1000 (12 fewer to 6 more) in the dose‐escalated RT group developing distant metastases. </p> <p>Dose‐escalated RT may increase overall late GI toxicity (RR 1.27, 95% CI 1.04 to 1.55; I<sup>2</sup> = 85%; 7 studies; 4328 participants; low‐certainty evidence); 92 more men per 1000 (14 more to 188 more) in the dose‐escalated RT group assuming overall late GI toxicity as 342 per 1000 in the conventional dose RT group. However, dose‐escalated RT may result in little to no difference in overall late GU toxicity (RR 1.12, 95% CI 0.97 to 1.29; I<sup>2</sup> = 51%; 7 studies; 4298 participants; low‐certainty evidence); 34 more men per 1000 (9 fewer to 82 more) in the dose‐escalated RT group assuming overall late GU toxicity as 283 per 1000 in the conventional dose RT group. </p> <p>Based on long‐term follow‐up (up to 36 months), dose‐escalated RT may result or probably results in little to no difference in the quality of life using 36‐Item Short Form Survey; physical health (MD ‐3.9, 95% CI ‐12.78 to 4.98; 1 study; 300 participants; moderate‐certainty evidence) and mental health (MD ‐3.6, 95% CI ‐83.85 to 76.65; 1 study; 300 participants; low‐certainty evidence), respectively. </p> </section> <section id="CD012817-sec-0007"> <h3 class="title" id="CD012817-sec-0007">Authors' conclusions</h3> <p>Compared to conventional dose RT, dose‐escalated RT probably results in little to no difference in time to death from prostate cancer, time to death from any cause, time to distant metastasis, and RT toxicities (except overall late GI toxicity). While dose‐escalated RT may increase overall late GI toxicity, it may result, or probably results, in little to no difference in physical and mental quality of life, respectively. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012817-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012817-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012817-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012817-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012817-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012817-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012817-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/id#CD012817-abs-0021">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012817-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012817-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD012817-abs-0022">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012817-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012817-abs-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012817-abs-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012817-abs-0016">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012817-abs-0002" lang="en"> <h3>Dose‐escalated radiotherapy for curative treatment in men with clinically localized prostate cancer </h3> <p><b>Review question</b> </p> <p>How does a higher radiation dose compare to a lower dose when treating prostate cancer that is limited to the prostate gland?  </p> <p><b>Background</b> </p> <p>Treatment for prostate cancer includes surgery, radiation therapy, hormone therapy, and chemotherapy. Radiation therapy (RT) is a treatment that uses beams of intense energy to kill cancer cells. So‐called dose‐escalated RT has an increased radiation dose compared to usual or 'normal' (conventional) dose RT, in order to better kill cancer, but that may also increase unwanted effects that come from the radiation hitting other organs like the bladder and rectum. We did this study to better understand how the two types of radiation compare.  </p> <p><b>Study characteristics</b> </p> <p>We found nine studies in 5437 men comparing dose‐escalated RT with conventional dose RT. Most of the patients were in their late 60s to early 70s, and most of them had early‐stage prostate cancer. </p> <p><b>Key results</b> </p> <p>Compared to conventional dose RT, dose‐escalated RT probably has little to no effect on the risk of dying of prostate cancer. It also probably results in little to no effect on severe bowel or urinary‐related unwanted effects in the long term. There is probably also little to no difference in the risk of dying from any cause or from developing spread to other organs (such as the bones or lymph nodes). Depending on the particular long‐term quality of life measure, dose‐escalated RT probably has or may have little to no effect on physical health and mental health, respectively. </p> <p><b>Quality of the evidence</b> </p> <p>The certainty of the evidence for all main outcomes was moderate or low. The true effect may be quite different from what this review shows. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012817-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012817-sec-0104"></div> <h3 class="title" id="CD012817-sec-0105">Implications for practice</h3> <section id="CD012817-sec-0105"> <p>Based on our findings, dose‐escalated RT probably results in little to no difference in time to death from prostate cancer, time to death from any cause, time to distant metastasis, and RT toxicities (except overall late GI toxicity), compared to conventional dose RT. Dose‐escalated RT may result or probably results in little to no difference in the quality of life. While dose‐escalated RT probably decreases time to biochemical recurrence, it may increase overall late GI toxicity. </p> </section> <h3 class="title" id="CD012817-sec-0106">Implications for research</h3> <section id="CD012817-sec-0106"> <p> <ul id="CD012817-list-0026"> <li> <p>We found only limited studies that were performed in Canada, Europe, and the USA. Therefore, similar studies performed in other countries would be valuable to validate these findings.  </p> </li> <li> <p>Given that the quality of life for cancer patients is a critical outcome, we need more studies that focus on this outcome considering the relatively low mortality rate of localized prostate cancer. </p> </li> <li> <p>In the modern era, IMRT and IGRT have become current standard techniques. However, half of the included studies used the 3DCRT technique. Therefore, we need more RCTs using the techniques in current clinical practice.   </p> </li> <li> <p> We reported some survival outcomes by risk subgroup, but this was based on limited data. In order to obtain an appropriate effect of dose‐escalated RT in prostate cancer patients, risk stratification studies should be undertaken. Elucidating these issues requires high‐quality research that has been specifically designed and adequately validated. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012817-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012817-sec-0008"></div> <div class="table" id="CD012817-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dose‐escalated RT compared to conventional dose RT for clinically localized and locally advanced prostate cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Dose‐escalated RT compared to conventional dose RT for clinically localized and locally advanced prostate cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> clinically localized and locally advanced prostate cancer <br/><b>Setting:  </b> likely outpatients<br/><b>Intervention:</b> dose‐escalated RT <br/><b>Comparison:</b> conventional dose RT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional dose RT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with dose‐escalated RT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><b>Time to death from prostate cancer</b> </p> <p>Follow‐up: assumed baseline risk at 10 years</p> <p> </p> <p>MCID: 3% absolute difference</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5231<br/>(8 RCTs<sup>1</sup>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.83</b><br/>(0.66 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Assumed baseline risk<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in time to death from prostate cancer. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1000<br/>(1 fewer to 0 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Severe RT toxicity </b> </p> <p><b>(grade ≥ 3)</b> </p> <p> </p> <p>Follow‐up: 5.1 to 8.7 years (median)</p> <p> </p> <p>MCID: 5% absolute difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late GI toxicity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4992<br/>(8 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.72</b><br/>(1.32 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in severe late RT toxicity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 more per 1000<br/>(10 more to 40 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late GU toxicity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4962<br/>(8 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.25</b><br/>(0.95 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/>(2 fewer to 23 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><b>Time to death from any cause</b> </p> <p>Follow‐up: assumed baseline risk at 10 years</p> <p> </p> <p>MCID: 3% absolute difference</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5437<br/>(9 RCTs<sup>1</sup>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.98</b><br/>(0.89 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Assumed baseline risk<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in time to death from any cause. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer per 1000<br/>(11 fewer to 9 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><b>Time to distant metastasis</b> </p> <p>Follow‐up: assumed baseline risk at 10 years</p> <p> </p> <p>MCID: 3% absolute difference</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3499<br/>(7 RCTs<sup>1</sup>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.83</b><br/>(0.57 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Assumed baseline risk<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in time to distant metastasis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 fewer per 1000<br/>(12 fewer to 6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Overall RT toxicity </b> </p> <p><b>(grade ≥ 1)</b> </p> <p> </p> <p>Follow‐up: 5.1 to 8.7 years (median)</p> <p> </p> <p>MCID: 5% absolute difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late GI toxicity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4328<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>LOW<sup>2, 4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.27</b><br/>(1.04 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT may increase overall late GI toxicity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 more per 1000<br/>(14 more to 188 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late GU toxicity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4298<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>LOW<sup>2, 4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.12</b><br/>(0.97 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT may result in little to no difference in overall late GU toxicity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 more per 1000<br/>(9 fewer to 82 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Quality of life</b> </p> <p> </p> <p>Follow‐up: 36 months (long term)</p> <p> </p> <p>MCID: 25% relative difference<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SF‐36 (SSPH)<br/>Scale from 0 (worst) to 100 (best) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>300<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The change from the baseline of SF‐36 was ‐4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 3.9 lower<br/>(12.78 lower to 4.98 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in quality of life (physical health). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SF‐36 (SSMH)</p> <p>Scale from 0 (worst) to 100 (best)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>300<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>LOW<sup>2, 4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The change from the baseline of SF‐36 was 0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 3.6 lower<br/>(83.85 lower to 76.65 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose‐escalated RT may result in little to no difference in quality of life (mental health). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>GI:</b> gastrointestinal; <b>GU:</b> genitourinary; <b>HR:</b> hazard ratio; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy; <b>SF‐36</b> : self‐administered short form‐36 quality of life questionnaire; <b>SSMH</b> : summary score mental health; <b>SSPH</b>: summary score physical health </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Median follow‐up range of the included studies was 5.1 to 14.3 years. </p> <p><sup>2</sup> Downgraded by one level for study limitations: unclear or high risk of bias for one or more domains among the included studies </p> <p><sup>3</sup> Estimates for control event rates for survival rate come from  <a href="./references#CD012817-bbs2-0045" title="HamdyFC , DonovanJL , LaneJA , MasonM , MetcalfeC , HoldingP , et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine2016;375:1415-24.">Hamdy 2016</a>. </p> <p><sup>4</sup> Downgraded by one level for imprecision: confidence interval crosses the assumed threshold of clinically important difference </p> <p><sup>5</sup> Estimates for MCID as 25% relative difference (20 points) from the baseline (approximately 80 points) (<a href="./references#CD012817-bbs2-0044" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision [GRADE leitlinien: 6. Einschätzung der qualität der evidenz — unzureichende präzision]. Journal of Clinical Epidemiology2012;106:677-88.">Guyatt 2012</a>) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012817-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012817-sec-0009"></div> <section id="CD012817-sec-0010"> <h3 class="title" id="CD012817-sec-0010">Description of the condition</h3> <p>Prostate cancer is the second most common malignancy in men after lung cancer worldwide, accounting for 1,276,106 new cases and causing 358,989 deaths (3.8% of all cancer‐related deaths in men) in 2018 (<a href="./references#CD012817-bbs2-0031" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer Journal for Clinicians2018;68(6):394-424. [DOI: https://doi.org/10.3322/caac.21492]">Bray 2018</a>). The incidence of prostate cancer is higher in developed areas where prostate‐specific antigen (PSA) testing is more common (<a href="./references#CD012817-bbs2-0042" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. globocan.iarc.fr (accessed 16 August 2014).">Ferlay 2013</a>). An increase in the incidence of prostate cancer due to PSA screening has resulted in some stage shift, with more men now presenting with prostate cancer that is confined to the prostate and seminal vesicles, without detectable metastatic disease involving lymph nodes, bones, or other organs (cT1‐3N0M0) (<a href="./references#CD012817-bbs2-0028" title="AminMB , GreeneFL , EdgeSB , ComptonCC , GershenwaldJE , BrooklandRK , et al. AJCC Cancer Staging Manual. 8th edition. Springer, 2017.">Amin 2017</a>). Based on risk factors, acceptable options of treatment for clinically localized prostate cancer include radical prostatectomy, external beam radiation therapy (EBRT), brachytherapy, active surveillance, hormonal therapy, and watchful waiting (<a href="./references#CD012817-bbs2-0029" title="BekelmanJE , RumbleRB , ChenRC , PisanskyTM , FinelliA , FeiferA , et al. Clinically localized prostate cancer: ASCO Clinical Practice Guideline endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. Journal of Clinical Oncology2018;36(32):3251-8.">Bekelman 2018</a>; <a href="./references#CD012817-bbs2-0063" title="MottetN , BerghRCN , BriersE , BroeckTV , CumberbatchMG , De SantisM , et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer — 2020 Update. Part 1: Screening, diagnosis, and local treatment with curative intent. European Urology2021;79(2):243-62.">Mottet 2021</a>; <a href="./references#CD012817-bbs2-0064" title="NICE Guideline Updates Team (UK). Prostate cancer: diagnosis and management 2019. europepmc.org/books/n/niceng131 (accessed 12 November 2021).">NICE 2019</a>; <a href="./references#CD012817-bbs2-0071" title="SandaMG , CadedduJA , KirkbyE , ChenRC , CrispinoT , FontanarosaJ , et al. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part I: Risk stratification, shared decision making, and care options. Journal of Urology2018;199(3):683-90.">Sanda 2018</a>). </p> </section> <section id="CD012817-sec-0011"> <h3 class="title" id="CD012817-sec-0011">Description of the intervention</h3> <p>Definitive radiotherapy (RT), where ionizing radiation (delivered either using EBRT, brachytherapy, or a combination of both) is delivered to the prostate, is one of the principal treatment options aimed at curing prostate cancer. For many decades, the dose of RT used to treat prostate cancer has been limited to less than 70 Gy to 72 Gy with a 1.8 Gy to 2.0 Gy daily fractionation schedule in order to limit the dose to adjacent normal tissues and to limit the resulting acute and late toxicity to acceptable levels. With these 'conventional' doses, prostate cancer is not always eradicated and persists or later recurs in a substantial proportion of men. Recurrence may occur locally within the prostate and surrounding tissues or lymph nodes, or distantly (commonly within bones) and may ultimately be fatal. Clinically evident local or distant recurrence is usually preceded by biochemical failure, with an elevation of PSA in the blood. Biochemical failure after RT provides a surrogate measure of the failure of EBRT to cure prostate cancer, with long‐term studies showing PSA failure in 29% to 80% of men who receive total doses of 65 Gy to 70 Gy (<a href="./references#CD012817-bbs2-0046" title="HancockSL , CoxRS , BagshawMA . Prostate-specific antigen after radiotherapy for prostate cancer: a re-evaluation of long term biochemical control and the kinetics of recurrence in patients treated at Stanford University. Journal of Urology1995;154(4):1412-7.">Hancock 1995</a>; <a href="./references#CD012817-bbs2-0084" title="ZietmanAL , CoenJJ , DallowKC , ShipleyWU . The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. International Journal of Radiation Oncology Biology Physics1995;32(2):287-92.">Zietman 1995</a>). PSA failure has been shown to predict a higher risk of subsequent clinical failure and death from prostate cancer (<a href="./references#CD012817-bbs2-0054" title="HorwitzEM , ViciniFA , ZiajaEL , DmuchowskiCF , StrombergJS , MartinezAA . The correlation between the ASTRO consensus panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. International Journal of Radiation Oncology Biology Physics1998;41(2):267-72.">Horwitz 1998</a>; <a href="./references#CD012817-bbs2-0067" title="PollackA , HanlonAL , MovsasB , HanksGE , UzzoR , HorwitzEM . Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics2003;57(1):19-23.">Pollack 2003</a>; <a href="./references#CD012817-bbs2-0068" title="PoundCR , PartinAW , EisenbergerMA , ChanDW , PearsonJD , WalshPC . Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association1999;281(17):1591-7.">Pound 1999</a>; <a href="./references#CD012817-bbs2-0078" title="ViciniFA , KestinLL , MartinezAA . The correlation of serial prostate-specific antigen measurements with clinical outcome after external beam radiotherapy of patients for prostate carcinoma. Cancer2000;88(10):2305-18.">Vicini 2000</a>). </p> <p>Prostate cancer is a relatively radioresistant tumor and needs higher doses for sterilization (indicating the elimination of all prostate cancer cells) in comparison with other malignancies (<a href="./references#CD012817-bbs2-0081" title="ZelefskyMJ , FuksZVI , HuntM , LeeHJ , LombardiD , LingCC , et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Journal of Urology2001;166(3):876-81.">Zelefsky 2001</a>). This is the rationale for increasing the dose of RT. The radiation dose that can be delivered using EBRT is limited by the radiation tolerance of normal structures in the area, including the rectum, bladder, small bowel, and prostatic urethra. In the past, doses above 70 Gy caused unacceptably high rates of severe acute and late rectal and bladder toxicity (<a href="./references#CD012817-bbs2-0049" title="HartfordAC , NiemierkoA , AdamsJA , UrieMM , ShipleyWU . Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms. International Journal of Radiation Oncology Biology Physics1996;36(3):721-30.">Hartford 1996</a>; <a href="./references#CD012817-bbs2-0061" title="MichalskiJM , GayH , JacksonA , TuckerSL , DeasyJO . Radiation dose-volume effects in radiation-induced rectal injury. International Journal of Radiation Oncology Biology Physics2010;76(Suppl 3):S123-9.">Michalski 2010</a>; <a href="./references#CD012817-bbs2-0076" title="StoreyMR , PollackA , ZagarsG , SmithL , AntolakJ , RosenI . Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635-42.">Storey 2000</a>). Technical advances in RT planning and treatment now allow delivery of higher EBRT doses to the prostate, with relative sparing of the nearby normal tissues, with the distribution of RT doses conforming more to the prostate and seminal vesicle shape (<a href="./references#CD012817-bbs2-0048" title="HardcastleN , DaviesA , FooK , MillerA , MetcalfePE . Rectal dose reduction with IMRT for prostate radiotherapy. Journal of Medical Imaging and Radiation Oncology2010;54(3):235-48.">Hardcastle 2010</a>; <a href="./references#CD012817-bbs2-0062" title="MichalskiJM , YanY , WatkinsBD , BoschWR , WinterK , GalvinJM , et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. International Journal of Radiation Oncology Biology Physics2013;87(5):932-8.">Michalski 2013</a>; <a href="./references#CD012817-bbs2-0065" title="PalmaD , VollansE , JamesK , NakanoS , MoiseenkoV , ShafferR , et al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. International Journal of Radiation Oncology Biology Physics2008;72(4):996-1001.">Palma 2008</a>). </p> <p>A recent large retrospective trial of men identified through the National Cancer Database suggested an improvement in survival with increasing dosage (<a href="./references#CD012817-bbs2-0058" title="KalbasiA , LiJ , BermanAT , Swisher-McClureS , SmaldoneM , UzzoRG , et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA2015;1(7):897-906.">Kalbasi 2015</a>). Such non‐randomized comparisons may be associated with bias related to patients treated with higher doses being treated more recently, with improved imaging and planning, and shorter follow‐up. Results from several randomized controlled trials (RCTs) studying dose‐escalation have shown a reduction in PSA failure, but overall survival and metastasis‐free survival and toxicity outcomes are unclear (<a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>). </p> <p>Dose escalation can also be achieved using brachytherapy (where radiation is delivered using radioisotopes inserted temporarily or permanently into the prostate tissue). This technique involves the use of additional specialized equipment, expertise, and expense and is operator‐dependent. Given this, and the potential to confound the comparison because of radiobiological variation due to dose fractionation or dose‐rate effects, and heterogeneity of dose or geographic miss depending on seed or catheter placement, this review will be limited to dose escalation using EBRT. In addition, heavy particle radiation therapy including proton therapy has recently emerged. However, it is not widely used or is less cost‐effective for most patients with prostate cancer and, since inclusion may cause confusion in the results, it was decided that this therapy should be excluded from the review. </p> </section> <section id="CD012817-sec-0012"> <h3 class="title" id="CD012817-sec-0012">How the intervention might work</h3> <p>The use of RT doses higher than RT 70 Gy to 72 Gy may increase the ability to sterilize and therefore cure prostate cancer. There are non‐randomized data to suggest that dose escalation reduces the risk of PSA failure (<a href="./references#CD012817-bbs2-0039" title="EadeTN , HanlonAL , HorwitzEM , BuyyounouskiMK , HanksGE , PollackA . What dose of external-beam radiation is high enough for prostate cancer?International Journal of Radiation Oncology Biology Physics2007;68(3):682-9.">Eade 2007</a>; <a href="./references#CD012817-bbs2-0047" title="HanksGE , HanlonAL , EpsteinB , HorwitzEM . Dose response in prostate cancer with 8-12 years' follow-up. International Journal of Radiation Oncology Biology Physics2002;54(2):427-35.">Hanks 2002</a>; <a href="./references#CD012817-bbs2-0081" title="ZelefskyMJ , FuksZVI , HuntM , LeeHJ , LombardiD , LingCC , et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. Journal of Urology2001;166(3):876-81.">Zelefsky 2001</a>; <a href="./references#CD012817-bbs2-0082" title="ZelefskyMJ , YamadaY , FuksZ , ZhangZ , HuntM , CahlonO , et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. International Journal of Radiation Oncology Biology Physics2008;71(4):1028-33.">Zelefsky 2008</a>). PSA failure has been shown to increase the risk of subsequent clinical failure and death from prostate cancer (<a href="./references#CD012817-bbs2-0054" title="HorwitzEM , ViciniFA , ZiajaEL , DmuchowskiCF , StrombergJS , MartinezAA . The correlation between the ASTRO consensus panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. International Journal of Radiation Oncology Biology Physics1998;41(2):267-72.">Horwitz 1998</a>; <a href="./references#CD012817-bbs2-0067" title="PollackA , HanlonAL , MovsasB , HanksGE , UzzoR , HorwitzEM . Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics2003;57(1):19-23.">Pollack 2003</a>; <a href="./references#CD012817-bbs2-0068" title="PoundCR , PartinAW , EisenbergerMA , ChanDW , PearsonJD , WalshPC . Natural history of progression after PSA elevation following radical prostatectomy. Journal of the American Medical Association1999;281(17):1591-7.">Pound 1999</a>; <a href="./references#CD012817-bbs2-0070" title="RoachM , HanksG , ThamesH , SchellhammerP , ShipleyWU , SokolGH , et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology Biology Physics2006;65(4):965-74.">Roach 2006</a>; <a href="./references#CD012817-bbs2-0078" title="ViciniFA , KestinLL , MartinezAA . The correlation of serial prostate-specific antigen measurements with clinical outcome after external beam radiotherapy of patients for prostate carcinoma. Cancer2000;88(10):2305-18.">Vicini 2000</a>). If dose escalation can be safely delivered (without increasing acute or late RT toxicity), higher tumor cell kill in the prostate may translate into clinically meaningful benefits for patients, in terms of cancer‐related outcomes including prostate cancer‐specific survival, distant metastasis‐free survival, and overall survival. </p> <p>There are potential adverse events of the intervention. Dose escalation may be associated with increased acute and late RT toxicity, although this may be mitigated by increased treatment delivery sophistication including the use of image guidance and strategies to reduce dose to bowel tissue (<a href="./references#CD012817-bbs2-0083" title="ZelefskyMJ , KollmeierM , CoxB , FidaleoA , SperlingD , PeiX , et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. International Journal of Radiation Oncology Biology Physics2012;84(1):125-9.">Zelefsky 2012</a>). Dose escalation using conventional fractionation is resource‐intensive and will increase the number of visits men make to the Department of Radiation Oncology and may have increased costs for the patient and society. On the other hand, dose‐escalated hypofractionation may alleviate the burden of frequent visits by reducing the number of daily fractionated treatments. </p> </section> <section id="CD012817-sec-0013"> <h3 class="title" id="CD012817-sec-0013">Why it is important to do this review</h3> <p> <ol id="CD012817-list-0001"> <li> <p>The effects of dose escalation on clinically relevant endpoints including overall survival and metastasis‐free survival are unclear. Although dose‐escalated RT may reduce PSA failure (a surrogate outcome), not all men with PSA failure develop clinically evident loco‐regional or distant failure or die of prostate cancer. There is a variable and often long lag time between biochemical failure and the development of clinically evident local, regional, or distant metastatic disease (<a href="./references#CD012817-bbs2-0085" title="ZumstegZS , SprattDE , RomesserPB , PeiX , ZhangZ , PolkinghornW , et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. European Urology2015;67:1009-16.">Zumsteg 2015</a>). This is especially true in older men, who have competing risks for mortality. </p> </li> <li> <p>Toxicity may be increased with dose‐escalated RT.</p> </li> <li> <p>Higher doses using conventional fractionation (1.8 to 2 Gy per fraction) increase overall treatment time which may be onerous for some men and resource‐intensive for RT departments. </p> </li> </ol> </p> <p>Although existing systematic reviews have compared conventional dose and dose‐escalated RT used in the treatment of prostate cancer (<a href="./references#CD012817-bbs2-0055" title="HouZ , LiG , BaiS . High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta‑analysis of long-term follow-up. Journal of Cancer Research and Clinical Oncology2015;141:1063-71. [DOI: 10.1007/s00432-014-1813-1]">Hou 2015</a>; <a href="./references#CD012817-bbs2-0077" title="VianiGA , StefanoEJ , AfonsoSL . Higher than conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. International Journal of Radiation Oncology Biology Physics2009;74(5):1405.">Viani 2009</a>), none have yet used the same rigorous methodology as Cochrane Reviews, which includes the application of a GRADE approach. This Cochrane Review of RCTs will provide the most reliable evidence of the efficacy and toxicity of dose escalation. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012817-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012817-sec-0014"></div> <p>To assess the effects of dose‐escalated RT in comparison with conventional dose RT for curative treatment of clinically localized and locally advanced prostate cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012817-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012817-sec-0015"></div> <section id="CD012817-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012817-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included only parallel randomized trials. We excluded cross‐over and cluster‐randomized trials as they are not relevant to this comparison and did not consider quasi‐randomized controlled trials or observational studies, given their increased risk of selection bias. We included studies regardless of their publication status or the language of publication. </p> </section> <section id="CD012817-sec-0018"> <h4 class="title">Types of participants</h4> <p>Men with clinically localized or locally advanced prostate cancer, which we defined as histologically confirmed invasive prostate adenocarcinoma without regional lymph node involvement or distant metastatic disease (T1‐3 N0 M0) (<a href="./references#CD012817-bbs2-0028" title="AminMB , GreeneFL , EdgeSB , ComptonCC , GershenwaldJE , BrooklandRK , et al. AJCC Cancer Staging Manual. 8th edition. Springer, 2017.">Amin 2017</a>). We did not consider participant age or comorbidities in determining study eligibility. If studies were identified which included only a subset of relevant participants, they were included if the relevant data were reported separately. </p> </section> <section id="CD012817-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We investigated the following comparisons of intervention versus control/comparator.</p> <section id="CD012817-sec-0020"> <h5 class="title">Experimental interventions</h5> <p>Dose‐escalated RT, defined as a total dose of ≥ 74 Gy (equivalent dose in the 2 Gy fractions [EQD<sub>2</sub>] for fraction dose range from 1.8 Gy to 2.5 Gy, α/β ratio = 1.5 (<a href="./references#CD012817-bbs2-0032" title="BrennerDJ , Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. International Journal of Radiation Oncology Biology Physics1999;43(5):1095-101.">Brenner 1999</a>)). </p> </section> <section id="CD012817-sec-0021"> <h5 class="title">Comparator interventions</h5> <p>Conventional dose RT of &lt; 74 Gy (EQD<sub>2</sub> for fraction dose range from 1.8 Gy to 2.0 Gy, α/β ratio = 1.5 (<a href="./references#CD012817-bbs2-0032" title="BrennerDJ , Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. International Journal of Radiation Oncology Biology Physics1999;43(5):1095-101.">Brenner 1999</a>)). </p> </section> <section id="CD012817-sec-0022"> <h5 class="title">Inclusion criteria</h5> <p>RT had to be conventionally fractionated (delivered at 1.8 Gy to 2.0 Gy per fraction) or mildly hypo‐fractionated (delivered at ≤ 2.5 Gy per fraction) in both control and experimental arms. The dose had to be either prescribed to the International Commission on Radiation Units &amp; Measurements (ICRU) reference point (<a href="./references#CD012817-bbs2-0056" title="International Commission on Radiation Units &amp; Measurements. Prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU Report 50), ICRU Report 62. Bethesda (MD): International Commission on Radiation Units &amp; Measurements, 1999. [ISBN: 0-913394-61-0]">ICRU 1999</a>) or according to <a href="./references#CD012817-bbs2-0057" title="International Commission on Radiation Units &amp; Measurements. Report 83: Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). Journal of the International Commission on Radiation Units &amp; Measurements2010;10(1):1-106. [ISSN: 1473-6691]">ICRU 2010</a>. EBRT could be delivered using (3‐dimension conformal radiation therapy) 3DCRT, or using highly conformal RT including intensity‐modulated radiation therapy (IMRT), volume modulated rotational arc therapy, and helical therapy (tomotherapy). Studies where RT was delivered using 3DCRT in the control arm and highly conformal RT in the experimental arm were permitted. Studies were eligible irrespective of whether image guidance was used to deliver the intervention. The treated volume had to include the prostate, with or without the seminal vesicles, provided the target volumes were the same for both arms. Pelvic node RT was permitted provided the target volumes were the same in both study arms. Concomitant interventions such as the use of neoadjuvant, concurrent, or adjuvant therapy (androgen deprivation, cytotoxic drugs, or other novel agents) were permitted, provided it was applied equally to both arms to avoid confounding. </p> </section> <section id="CD012817-sec-0023"> <h5 class="title">Exclusion criteria</h5> <p>Trials using brachytherapy as a sole modality or as a boost were excluded. Particle therapy such as protons or carbon ions was also excluded.  </p> </section> </section> <section id="CD012817-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>We included studies regardless of whether they measured the outcomes to be assessed in this review. </p> <section id="CD012817-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012817-list-0002"> <li> <p>Time to death from prostate cancer</p> </li> <li> <p>Severe RT toxicity</p> </li> </ul> </p> </section> <section id="CD012817-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012817-list-0003"> <li> <p>Time to death from any cause</p> </li> <li> <p>Time to distant metastasis</p> </li> <li> <p>Overall RT toxicity</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Time to biochemical recurrence</p> </li> </ul> </p> <section id="CD012817-sec-0027"> <h6 class="title">Method and timing of outcome measurement</h6> <p> <ul id="CD012817-list-0004"> <li> <p>Time to death from prostate cancer (time‐to‐event outcome): as measured from the time of randomization to death due to prostate cancer </p> </li> <li> <p>Severe RT toxicity (dichotomous outcome): grade 3 or higher toxicity occurring during RT or within 90 days after RT completed (acute) or lasting &gt; 90 days after RT completed (late), including GU and GI complications (using trial‐specific instruments including, but not limited to the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) system (<a href="./references#CD012817-bbs2-0036" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology Biology Physics1995;31(5):1341-6.">Cox 1995</a>) or National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) (<a href="./references#CD012817-bbs2-0034" title="ColevasAD , SetserA . The NCI common terminology criteria for adverse events (CTCAE) v 3.0 is the new standard for oncology clinical trials. Journal of Clinical Oncology2004;22: Suppl 14:6098.">Colevas 2004</a>)) </p> </li> <li> <p>Time to death from any cause (time‐to‐event outcome): as measured from the time of randomization to death due to any cause. </p> </li> <li> <p>Time to distant metastasis (time‐to‐event outcome): as measured from the time of randomization to metastasis such as distant recurrence in bones, lymph nodes, or other visceral organs </p> </li> <li> <p>Overall RT toxicity (dichotomous outcome): any grade toxicity occurring during RT or within 90 days after RT completed (acute) or lasting &gt; 90 days after RT completed (late), including GU and GI complications. Individual protocol‐based definitions will be used, but not limited to the RTOG/EORTC system (<a href="./references#CD012817-bbs2-0036" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology Biology Physics1995;31(5):1341-6.">Cox 1995</a>) or NCI CTCAE (<a href="./references#CD012817-bbs2-0034" title="ColevasAD , SetserA . The NCI common terminology criteria for adverse events (CTCAE) v 3.0 is the new standard for oncology clinical trials. Journal of Clinical Oncology2004;22: Suppl 14:6098.">Colevas 2004</a>). </p> </li> <li> <p>Quality of life (continuous outcome): final values or changes from baseline measured by validated instruments, such as the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30) (<a href="./references#CD012817-bbs2-0026" title="AaronsonNK , AhmedzaiS , BerganB , BullingerM , CullA , DuezNJ , et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. Journal of National Cancer Institute1993;85:365-76.">Aaronson 1993</a>), 12‐Item Short‐Form Health Survey (SF‐12) (<a href="./references#CD012817-bbs2-0079" title="Ware JrJE , KosinskiM , Keller SD . A 12-item short-form health survey construction of scales and preliminary tests of reliability and validity. Medical Care1996;34(3):220-33.">Ware 1996</a>), or Functional Assessment of Cancer Therapy‐Prostate (FACT‐P) (<a href="./references#CD012817-bbs2-0041" title="EsperP , MoF , ChodakG , SinnerM , CellaD , PientaKJ . Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy Prostate instrument. Urology1997;50(6):920-8.">Esper 1997</a>). These were categorized as occurring ≤ 12 months (short term) or &gt; 12 months (long term) after treatment. </p> </li> <li> <p>Time to biochemical recurrence (time‐to‐event outcome): defined as a rise of 2 ng/mL or more above the PSA nadir after EBRT with or without hormonal therapy, dated 'at call' (Phoenix definition, <a href="./references#CD012817-bbs2-0070" title="RoachM , HanksG , ThamesH , SchellhammerP , ShipleyWU , SokolGH , et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology Biology Physics2006;65(4):965-74.">Roach 2006</a>) </p> </li> </ul> </p> <p>We considered minimally clinically important differences (MCID) for review outcomes to rate the certainty of the evidence for imprecision in the Summary of findings table as follows: </p> <p> <ul id="CD012817-list-0005"> <li> <p>Time to death from prostate cancer, time to death from any cause, time to distant metastasis, and time to biochemical recurrence: 3% absolute difference </p> </li> <li> <p>RT Toxicity: 5% absolute difference</p> </li> <li> <p>Quality of life: 25% relative difference or based on published MCID, if available</p> </li> </ul> </p> <p>For all outcomes except quality of life, for which we found an established MCID reported in the literature, all proposed thresholds were based on the clinical experience of the review authors. </p> <p>The main time point of interest in our study was the end of the trial (defined as the time point with the longest follow‐up duration as measured from randomization). </p> </section> <section id="CD012817-sec-0028"> <h6 class="title">Main outcomes for Summary of findings table</h6> <p> <ul id="CD012817-list-0006"> <li> <p>Time to death from prostate cancer</p> </li> <li> <p>Severe late RT toxicity</p> </li> <li> <p>Time to death from any cause</p> </li> <li> <p>Time to distant metastasis</p> </li> <li> <p>Overall late RT toxicity</p> </li> <li> <p>Long‐term quality of life</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012817-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed a comprehensive search with no restriction on the language of publication or publication status. We re‐ran searches within six months prior to the anticipated publication of the review. </p> <section id="CD012817-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database to 20 July 2022:</p> <p> <ul id="CD012817-list-0007"> <li> <p>Cochrane Library via Wiley (from 1991);</p> </li> <li> <p>MEDLINE via Ovid (from 1946);</p> </li> <li> <p>Embase via Ovid (from 1947);</p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature (LILACS; <a href="http://www.bireme.br/" target="_blank">www.bireme.br/</a>; from 1982); </p> </li> <li> <p>Scopus (from 1966);</p> </li> <li> <p>Web of Science (from 1900).</p> </li> </ul> </p> <p>We also searched the following:</p> <p> <ul id="CD012817-list-0008"> <li> <p>ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov/</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>); </p> </li> <li> <p>Grey literature repository from the current Grey Literature Report (<a href="http://www.greylit.org/" target="_blank">www.greylit.org/</a>). </p> </li> </ul> </p> </section> <section id="CD012817-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, reviews, meta‐analyses, and health technology assessment reports. We contacted the study authors of included trials to identify any further studies that we may have missed. We have searched abstract proceedings of relevant meetings for the following: </p> <p> <ul id="CD012817-list-0009"> <li> <p>American Society of Clinical Oncology (ASCO);</p> </li> <li> <p>American Society for Radiation Oncology (ASTRO);</p> </li> <li> <p>European Society for Therapeutic Radiology and Oncology (ESTRO);</p> </li> <li> <p>American Urological Association (AUA); and</p> </li> <li> <p>European Association of Urology (EAU).</p> </li> </ul> </p> </section> </section> <section id="CD012817-sec-0032"> <h3 class="title" id="CD012817-sec-0032">Data collection and analysis</h3> <section id="CD012817-sec-0033"> <h4 class="title">Selection of studies</h4> <p>We used systematic review management software (<a href="./references#CD012817-bbs2-0040" title="EndNote. Version Version X9.2. Philadelphia: Clarivate Analytics, 2020.">EndNote 2020</a>; <a href="./references#CD012817-bbs2-0035" title="Covidence Systematic Review Software. Melbourne (VIC): Veritas Health Innovation, accessed prior to 3 July 2017. Available from www.covidence.org.">Covidence</a>) to identify and remove potential duplicate records. Two of the reviewers (from Kim S, Kong JH, Lee Y, Kang TW, Kong T, or You SH) independently scanned the abstract, title, or both, of the remaining records retrieved, to determine which studies should be assessed further. Two reviewers (Kim S and Kong JH) investigated all potentially relevant records as full text, mapped records to studies, and classified studies as included studies, excluded studies, studies awaiting classification, or ongoing studies in accordance with the criteria provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012817-bbs2-0053" title="Higgins JPT , Thomas J , Chandler J , Cumpston M , Li T , Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.0.">Higgins 2019</a>). </p> <p>We resolved any discrepancies through consensus or recourse to a third review author (You SH). If the resolution of a disagreement was not possible, we designated the study as awaiting classification and contacted the study authors for clarification. We documented reasons for the exclusion of studies that may have reasonably been expected to be included in the review in the <a href="./references#CD012817-sec-0130" title="">Characteristics of excluded studies</a> table. We presented an adapted PRISMA flow diagram (<a href="#CD012817-fig-0001">Figure 1</a>) showing the process of study selection (<a href="./references#CD012817-bbs2-0059" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology2009;62(10):e1-34.">Liberati 2009</a>). </p> <div class="figure" id="CD012817-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Prisma flow diagram" data-id="CD012817-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Prisma flow diagram</p> </div> </div> </div> </section> <section id="CD012817-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data abstraction form that we piloted.</p> <p>For studies that fulfilled the inclusion criteria, two review authors (Kim S and Kong JH) independently abstracted the following information, which is provided in the <a href="./references#CD012817-sec-0129" title="">Characteristics of included studies</a> table: </p> <p> <ul id="CD012817-list-0010"> <li> <p>Study design;</p> </li> <li> <p>Study setting and country;</p> </li> <li> <p>Study dates (if dates were not available, this was reported as such);</p> </li> <li> <p>Participant inclusion and exclusion criteria;</p> </li> <li> <p>Participant details, baseline demographics;</p> </li> <li> <p>The number of participants by study and by study arm;</p> </li> <li> <p>Details of relevant experimental and comparator interventions including:</p> <ul id="CD012817-list-0011"> <li> <p>Tumor (T), Node (N), Metastasis (M) stage;</p> </li> <li> <p>PSA prior to randomization;</p> </li> <li> <p>Pathological factors including Gleason score;</p> </li> <li> <p>Imaging used to exclude nodal or distant metastatic disease;</p> </li> <li> <p>Detail about RT including radiation dose, number of fractions, dose per fraction, volume treated, planning technique (conventional versus highly conformal and method), quality assurance procedures performed (to investigate the quality of radiation delivered), image guidance use; and </p> </li> <li> <p>Use of androgen deprivation;</p> </li> </ul> </li> <li> <p>Definitions of relevant outcomes, and method and timing of outcome measurement as well as any relevant subgroups; </p> </li> <li> <p>Study funding sources; and</p> </li> <li> <p>Declarations of interest of primary investigators.</p> </li> </ul> </p> <p>We extracted outcome data relevant to this Cochrane Review as needed for the calculation of summary statistics and measures of variance. For dichotomous outcomes (should data be available e.g. for quality of life measures), we attempted to obtain numbers of events and totals from the population(s) to prepare a 2 × 2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain the means and standard deviations (SDs) or data necessary to calculate this information. For time‐to‐event outcomes, we obtained hazard ratios (HRs) with corresponding measures of variance or data necessary to calculate this information. </p> <p>We resolved any disagreements by discussion or, if required, by consultation with a third review author (You SH). </p> <p>We provided information, including a trial identifier, about potentially relevant ongoing studies in a <a href="./references#CD012817-sec-0131" title="">Characteristics of ongoing studies</a> table. </p> <p>We attempted to contact the authors of included studies to obtain key missing data, as required. </p> <section id="CD012817-sec-0035"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary study, we maximized the yield of information by mapping all publications to unique studies and collating all available data. We used the most complete dataset aggregated across all known publications. In case of doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD012817-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (Kim S and Kong JH) assessed the risk of bias of each study independently. We resolved the disagreement by consensus, or by consultation with a third review author (You SH). </p> <p>We assessed the risk of bias using Cochrane's Risk of bias assessment tool (<a href="./references#CD012817-bbs2-0053" title="Higgins JPT , Thomas J , Chandler J , Cumpston M , Li T , Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.0.">Higgins 2019</a>). We assessed the following domains: </p> <p> <ol id="CD012817-list-0012"> <li> <p>Random sequence generation (selection bias);</p> </li> <li> <p>Allocation concealment (selection bias);</p> </li> <li> <p>Blinding of participants and personnel (performance bias);</p> </li> <li> <p>Blinding of outcome assessment (detection bias);</p> </li> <li> <p>Incomplete outcome data (attrition bias);</p> </li> <li> <p>Selective reporting (reporting bias);</p> </li> <li> <p>Other sources of bias.</p> </li> </ol> </p> <p>We judged the risk of bias domains as 'low risk', 'high risk', or 'unclear risk' and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012817-bbs2-0053" title="Higgins JPT , Thomas J , Chandler J , Cumpston M , Li T , Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.0.">Higgins 2019</a>). We present a Risk of bias summary figure (<a href="#CD012817-fig-0002">Figure 2</a>) to illustrate these findings. </p> <div class="figure" id="CD012817-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias judgments for individual included studies" data-id="CD012817-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias judgments for individual included studies</p> </div> </div> </div> <p>For selection bias (random sequence generation and allocation concealment), we evaluated the risk of bias at a trial level. </p> <p>For performance bias (blinding of participants and personnel), we considered all outcomes similarly susceptible to performance bias. </p> <p>For detection bias (blinding of outcome assessment), we evaluated the risk of bias separately for each outcome, and we grouped outcomes as susceptible to detection bias (subjective outcomes) or not susceptible to detection bias (objective outcomes). </p> <p>We defined the following endpoints as subjective outcomes with regard to detection bias: </p> <p> <ul id="CD012817-list-0013"> <li> <p>Time to death from prostate cancer</p> </li> <li> <p>RT toxicity (acute and late)</p> </li> <li> <p>Time to distant metastasis</p> </li> <li> <p>Quality of life</p> </li> </ul> </p> <p>We defined the following endpoints as objective outcomes:</p> <p> <ul id="CD012817-list-0014"> <li> <p>Time to death from any cause</p> </li> <li> <p>Time to biochemical recurrence</p> </li> </ul> </p> <p>We assessed attrition bias (incomplete outcome data) on an outcome‐specific basis and grouped outcomes with like judgments when reporting our findings in the Risk of bias tables. </p> <p>We further summarized the risk of bias across domains for each outcome in each included study, as well as across studies and domains for each outcome. </p> </section> <section id="CD012817-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RRs) with a 95% confidence interval (CI). We expressed continuous data as mean differences (MDs) with a 95% CI. We expressed time‐to‐event data as HRs with a 95% CI. </p> </section> <section id="CD012817-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. If studies had multiple eligible intervention arms, we attempted to combine groups to create a single pairwise comparison with the control arm to avoid double counting (<a href="./references#CD012817-bbs2-0053" title="Higgins JPT , Thomas J , Chandler J , Cumpston M , Li T , Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.0.">Higgins 2019</a>). </p> </section> <section id="CD012817-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain missing data from study authors, if feasible, and performed intention‐to‐treat analysis if data were available; we otherwise performed available case analyses. We investigated attrition rates, e.g. dropouts, losses to follow‐up and withdrawals, and critically appraised issues of missing data. We did not impute missing data. </p> </section> <section id="CD012817-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>There was no unexplained excessive heterogeneity.</p> <p>We identified heterogeneity through visual inspection of the forest plots to assess the amount of overlap of CIs, and the I² statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012817-bbs2-0051" title="HigginsJPT , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58.">Higgins 2002</a>; <a href="./references#CD012817-bbs2-0052" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. British Medical Journal (clinical research edition)2003;327(7414):557-60.">Higgins 2003</a>); we interpreted the I² statistic as follows: </p> <p> <ul id="CD012817-list-0015"> <li> <p>0% to 40%: may not be important;</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>If we detected heterogeneity, we first ensured we had not made an error and, if not, attempted to determine the possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD012817-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting.</p> <p>If we had included 10 studies or more investigating a particular outcome, we planned to use funnel plots to assess small study effects. But this was not done because fewer than 10 studies were included. Several explanations can be offered for the asymmetry of a funnel plot, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias. We, therefore, interpreted the results carefully. </p> </section> <section id="CD012817-sec-0042"> <h4 class="title">Data synthesis</h4> <p>Unless there was good evidence for homogeneous effects across studies, we summarized data using a random‐effects model (<a href="./references#CD012817-bbs2-0038" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7:177-88.">DerSimonian 1986</a>). We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. In addition, we performed statistical analyses according to the statistical guidelines contained in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012817-bbs2-0053" title="Higgins JPT , Thomas J , Chandler J , Cumpston M , Li T , Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane 2019. Available from www.training.cochrane.org/handbook/archive/v6.0.">Higgins 2019</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method (<a href="./references#CD012817-bbs2-0060" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719-48.">Mantel 1959</a>); for continuous outcomes, we used the inverse variance method; and for time‐to‐event outcomes, we used the generic inverse variance method. We used Review Manager 2020 software to perform analyses (<a href="./references#CD012817-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD012817-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out subgroup analyses with the investigation of interactions: </p> <p> <ul id="CD012817-list-0016"> <li> <p>Androgen deprivation therapy versus no androgen deprivation therapy, given the possibility that androgen deprivation therapy may negate the effect of dose escalation (<a href="./references#CD012817-bbs2-0073" title="SharifiN , GulleyJL , DahutWL . Androgen deprivation therapy for prostate cancer. JAMA2005;294(2):238-44.">Sharifi 2005</a>); </p> </li> <li> <p>Risk stratification (<a href="#CD012817-tbl-0002">Table 1</a>) according to <a href="./references#CD012817-bbs2-0037" title="D'AmicoAV , WhittingtonR , MalkowiczSB , SchultzD , BlankK , BroderickGA , et al. Biochemical outcome after radical prostatectomy, external beam radiotherapy, or interstitial radiation therapy for clinically localised prostate cancer. JAMA1998;280(11):969-74.">D'Amico 1998</a> to determine if the effect of dose escalation varied according to baseline risk (<a href="./references#CD012817-bbs2-0030" title="BoorjianSA , KarnesRJ , RangelLJ , BergstralhEJ , BluteML . Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. Journal of Urology2007;179(4):1354-60.">Boorjian 2008</a>; <a href="./references#CD012817-bbs2-0037" title="D'AmicoAV , WhittingtonR , MalkowiczSB , SchultzD , BlankK , BroderickGA , et al. Biochemical outcome after radical prostatectomy, external beam radiotherapy, or interstitial radiation therapy for clinically localised prostate cancer. JAMA1998;280(11):969-74.">D'Amico 1998</a>; <a href="./references#CD012817-bbs2-0050" title="HernandezDJ , NielsenME , HanM , PartinA . Contemporary evaluation of the D'Amico risk classification of prostate cancer. Urology2007;70(5):931-5.">Hernandez 2007</a>); </p> </li> <li> <p>Conventional fraction (1.8 Gy or 2.0 Gy) versus mild hypofraction (2.0 Gy &lt; fraction dose ≤ 2.5 Gy) according to fraction dose of dose‐escalated radiotherapy. </p> </li> </ul> </p> <div class="table" id="CD012817-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prostate cancer risk stratification</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Low risk</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gleason score &lt; 6, PSA &lt;10 ng/mL and clinical stage T1‐T2a</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intermediate risk</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gleason score 7, PSA 10‐20 ng/mL or clinical stage T2b</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>High risk</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gleason score 8‐10, PSA &gt; 20ng/mL or clinical stage &gt;T2c</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>PSA:</b> prostate‐specific antigen </p> </div> </div> <p>If we judged there were sufficient studies to do subgroup analysis, we compared them using the test for subgroup differences in <a href="./references#CD012817-bbs2-0069" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>. </p> </section> <section id="CD012817-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis limited to primary outcomes to explore the influence of the following factor (when applicable) on effect sizes: </p> <p> <ul id="CD012817-list-0017"> <li> <p>Restricting the analysis by taking into account the risk of bias, by excluding studies at 'high risk' or 'unclear risk' </p> </li> </ul> </p> </section> <section id="CD012817-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account issues related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results (<a href="./references#CD012817-bbs2-0043" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , SchünemannHJ , et al. GRADE: what is the "quality of evidence" and why is it important to clinicians?British Medical Journal (clinical research edition)2008;336(7651):995-8.'>Guyatt 2008</a>)<i>.</i> For each comparison, two review authors (Kim S and Kong JH) independently rated the certainty of the evidence for each outcome as 'high', 'moderate', 'low', or 'very low' using <a href="https://archie.cochrane.org/sections/documents/view?version=z2008180032561698371696576822502&amp;format=JATS#REF-GRADEpro-GDT" target="_blank">GRADEpro GDT</a>. We resolved any discrepancies by consensus, or, if needed, by arbitration by a third review author (You SH). For each comparison, we presented a summary of the evidence for the main outcomes in a Summary of findings table, which provides key information about the best estimate of the magnitude of the effect in relative terms and absolute differences (with corresponding CIs) for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in effect estimates for each outcome (<a href="https://archie.cochrane.org/sections/documents/view?version=z2008180032561698371696576822502&amp;format=JATS#REF-Guyatt-2011" target="_blank">Guyatt 2011</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2008180032561698371696576822502&amp;format=JATS#REF-Sch_x00fc_nemann-2011" target="_blank">Schünemann 2011</a>).  </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012817-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012817-sec-0046"></div> <section id="CD012817-sec-0047"> <h3 class="title">Description of studies</h3> <p>Details of included studies are presented elsewhere (<a href="./references#CD012817-sec-0129" title="">Characteristics of included studies</a>; <a href="#CD012817-tbl-0003">Table 2</a>; <a href="#CD012817-tbl-0004">Table 3</a>; <a href="#CD012817-tbl-0005">Table 4</a>). </p> <div class="table" id="CD012817-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial period [year to year]/</b> </p> <p><b>duration of<br/>follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study design/<br/>setting/<br/>country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention and comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No participants<br/>per arm/</b> </p> <p><b>age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Clinical stage (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Gleason score (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PSA (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk stratification</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. "><b>Creak 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1995 to 1997/13.7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/single center/United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Histologically proven T1b‐T3b N0 M0 adenocarcinoma of the prostate. There was no limit on pre‐treatment PSA levels, and any histological grade was accepted. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 74 Gy in 37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62/</p> <p>median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (26%) cT2 (56%) cT3 (18%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 (18%) 2 (68%) 3 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median 14 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 20%</p> <p>Intermediate: 27%</p> <p>High: 53%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 64 Gy in 32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64/</p> <p>median 66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (17%) cT2 (44%) cT3 (39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 (19%) 2 (77%) 3 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median 15 ng/mL</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]"><b>Heemsbergen 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1997 to 2003/</p> <p>110 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>4 centers/</p> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Histologically proven cT1a‐T4 adenocarcinoma of the prostate with an initial PSA level of &lt; 60 mg/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 78 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>333/</p> <p>mean 68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (70)</p> <p>cT2 (137)</p> <p>cT3 (123) </p> <p>cT4 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐6 (170)</p> <p>7 (116)</p> <p>8‐10 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐10 (137)</p> <p>10‐20 (126)</p> <p>20‐60 (70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 17.3%</p> <p>Intermediate: 26.8%</p> <p>High: 50.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 68 Gy in 34 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>331/</p> <p>mean 68.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (59)</p> <p>cT2 (149)</p> <p>cT3 (116)</p> <p>cT4 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐6 (162)</p> <p>7 (113)</p> <p>8‐10 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐10 (119)</p> <p>10‐20 (126)</p> <p>20‐60 (86)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]"><b>GETUG 06 trial</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1999 to 2002/</p> <p>61 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>17 centers/</p> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>&lt; 75 years, life expectancy &gt; 10 years with low Charlson score ≤ 2, T1 tumors were eligible if the Gleason score was at least VII or if the PSA level was at least 10 ng/mL, T2 and T3a, baseline PSA &lt; 50 ng/dL. Node dissection performed when the risk of positive nodes &gt; 10% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 80 Gy in 40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153/</p> <p>mean 66.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (28)</p> <p>cT2 (105)</p> <p>cT3 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7 (96)</p> <p>7 (47)</p> <p>8 (10)</p> <p>9 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (56)</p> <p>10‐20 (71)</p> <p>&gt; 20 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Intermediate: 71.5%</p> <p>High: 28.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153/</p> <p>mean 67.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (35)</p> <p>cT2 (100)</p> <p>cT3 (18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7 (96)</p> <p>7 (46)</p> <p>8 (10)</p> <p>9 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (62)</p> <p>10‐20 (67)</p> <p>&gt; 20 (24)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]"><b>Hoffman 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2001 to 2010/</p> <p>8.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>single‐center/</p> <p>United States</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Biopsy‐confirmed prostate adenocarcinoma, good performance status (Zubrod &lt; 2), cT1b‐T3b (AJCC 4th), PSA ≤ 20 ng/mL, Gleason score &lt; 10, and no clinical, radiographic, or pathologic evidence of nodal or bone metastasis. Men with cT3 disease were required to have a Gleason score &lt; 8 and pretreatment PSA ≤ 10 ng/mL. Men with Gleason score 8 or 9 diseases were required to have cT1/T2 disease and pretreatment PSA ≤ 10 ng/mL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 72 Gy in 30 fraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104/</p> <p>median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (71)</p> <p>cT2 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (33)</p> <p>7 (70)</p> <p>8 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 10 (95)</p> <p>10.1‐20 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 27.7%</p> <p>Intermediate: 71.3%</p> <p>High: 1.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 75.6 Gy in 42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102/</p> <p>median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (77)</p> <p>cT2 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (37)</p> <p>7 (64)</p> <p>8 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 10 (91)</p> <p>10.1‐20 (11)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]"><b>Pasalic 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1993 to 1998/</p> <p>14.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>single‐center/</p> <p>United States</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>cT1‐T3N0M0 (AJCC 1992), MD Anderson pathology review, pretreatment PSA ≤ 30 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 78 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151/</p> <p>median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (43)</p> <p>cT2 (74)</p> <p>cT3 (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6 (15)</p> <p>6 (59)</p> <p>7 (50)</p> <p>8 (22)</p> <p>9 (5)</p> <p>10 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (98)</p> <p>10‐20 (47)</p> <p>&gt; 20 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 20.6%</p> <p>Intermediate: 45.8%</p> <p>High: 33.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150/</p> <p>median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (45)</p> <p>cT2 (79)</p> <p>cT3 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6 (13)</p> <p>6 (57)</p> <p>7 (54)</p> <p>8 (19)</p> <p>9 (5)</p> <p>10 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (98)</p> <p>10‐20 (42)</p> <p>&gt; 20 (10)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. "><b>Dearnaley 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1998 to 2001/10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/multicenter/United Kingdom, New Zealand, Australia, Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men 18 years or older with histologically confirmed T1b–T3a, N0, M0 prostate cancer and prostate‐specific antigen (PSA) of less than 50 ng/mL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 74 Gy in 37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422/</p> <p>median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (103) cT2 (239) cT3 (76) unknown (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 6 (249) 7 (117) </p> <p>≥ 8 (54) unknown (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean 15.2 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low: 19%</p> <p>Intermediate: 36%</p> <p>High: 44%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 64 Gy in 32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>421/</p> <p>median 67 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (106) cT2 (236) cT3 (71) unknown (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 6 (261) 7 (105) </p> <p>≥ 8 (52) unknown (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean 15.6 ng/mL<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low: 19%</p> <p>Intermediate: 38%</p> <p>High: 43%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]"><b>Nabid 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2000 to 2010/</p> <p>11.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>11 centers/</p> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Histologically proven intermediate‐risk prostate cancer, Zubrod performance scale 0‐1, age 80 years, and no evidence of regional or metastatic disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 76 Gy in 38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200/</p> <p>median 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (95)</p> <p>cT2 (105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2)</p> <p>6 (45)</p> <p>7 (153)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐4.9 (33)</p> <p>5‐9.9 (68)</p> <p>10‐20 (99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Intermediate: 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200/</p> <p>median 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (99)</p> <p>cT2 (101)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2)</p> <p>6 (53)</p> <p>7 (145)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐4.9 (25)</p> <p>5‐9.9 (54)</p> <p>10‐20 (121)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. "><b>Michalski 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2002 to 2008/8.4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/104 centers/Canada and US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men with histologically confirmed prostate cancer diagnosed within 180 days of study randomization, a Zubrod performance scale of 0 to 1, clinical stage T1b to T2b with either a Gleason score of 2 to 6 and a PSA of at least 10 and less than 20 ng/mL (1:1 conversion to micrograms per liter) or Gleason score of 7 and a PSA of less than 15 ng/mL were eligible. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 79.2 Gy in 44 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>748/</p> <p>mean 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (423) cT2 (325)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐6 (126)</p> <p>7 (622)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (517) 10‐15 (187) 15‐20 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Intermediate: 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 70.2 Gy in 39 fractions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>751/</p> <p>mean 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (430) cT2 (321)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐6 (116)</p> <p>7 (635)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (525) 10‐15 (195) 15‐20 (31)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. "><b>Bruner 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2006 to 2009/</p> <p>5.8 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>multi‐center/</p> <p>United States, Canada, and Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men age &gt; 18 years, Zubrod performance scale &lt; 2, low‐risk prostate cancer (cT1b‐T2cN0M0 AJCC 6th, Gleason score 2–6 and PSA &lt; 10 ng/mL) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 70 Gy in 28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>550/</p> <p>median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (442)</p> <p>cT2 (108)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐4 (0)</p> <p>5‐6 (550)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4 (112)</p> <p>4‐10 (438)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 73.8 Gy in 41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542/</p> <p>median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (411)</p> <p>cT2 (131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐4 (2)</p> <p>5‐6 (540)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4 (106)</p> <p>4‐10 (436)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>AJCC:</b> American Joint Committee on Cancer<br/><b>C</b> : comparator<br/><b>I</b> : intervention<br/><b>n:</b> number of participants<br/><b>PSA:</b> prostate‐specific antigen (ng/mL)<br/><b>RCT:</b> randomized controlled trial </p> </div> </div> <div class="table" id="CD012817-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Description of interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Technique</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Image‐guided RT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Motion control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>RT QA</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>RT volume</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>CTV to PTV margins</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Androgen deprivation</b> <br/><b>(in both study  arms)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. "><b>Creak 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>± seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>either a 1 or 1.5 cm uniform margin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]"><b>Heemsbergen 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 94%</p> <p>IMRT 6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comfortably full bladder and without specific immobilization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>± seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5–10 mm margin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]"><b>GETUG 06 trial</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthogonal images</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty bladder and rectum 1 hour before the daily treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Central QA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>+ seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mm all dimensions except 5 mm posteriorly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nil</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]"><b>Hoffman 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>step‐and‐shoot IMRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fiducial markers or<br/>ultrasound </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>+ seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10–15 mm all dimensions except 4–8 mm posteriorly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]"><b>Pasalic 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CT scan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>+ seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25‐1.5 cm in the antero‐inferior dimension and 0.75‐1.0 cm in the posterosuperior dimension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nil</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. "><b>Dearnaley 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>± seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0 cm margin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]"><b>Nabid 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>+ seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10–15 mm all dimensions except 5–10 mm posteriorly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. "><b>Michalski 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 66.2% IMRT 33.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality control system compliant with National Cancer Institute guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prostate + proximal 1 cm of seminal vesicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5‐1.0 cm margin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nil</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. "><b>Bruner 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 21%</p> <p>IMRT 79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fiducial markers,<br/>ultrasound, or<br/>cone‐beam CT </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Central QA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4–10 mm margin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nil</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CT:</b> computed tomography<br/><b>CTV:</b> clinical target volume<br/><b>IMRT:</b> intensity‐modulated radiation therapy<br/><b>NR:</b> not reported<br/><b>PTV:</b> planning target volume<br/><b>RT:</b> radiotherapy<br/><b>QA:</b> quality assurance<br/><b>3DCRT:</b> three‐dimensional conformal radiation therapy </p> </div> </div> <div class="table" id="CD012817-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Equivalent dose in 2 Gy fractions of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose‐escalated RT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose per fraction</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>EQD<sub>2</sub> (α/β = 1.5)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conventional RT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose per fraction</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>EQD<sub>2</sub> (α/β = 1.5)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. "><b>Creak 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy in 37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy in 32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]"><b>Heemsbergen 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68 Gy in 34 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]"><b>GETUG 06 trial</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 Gy in 40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy in 35 fractions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]"><b>Hoffman 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 Gy in 30 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.23Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.6 Gy in 42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.28Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]"><b>Pasalic 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. "><b>Dearnaley 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy in 37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy in 32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]"><b>Nabid 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 Gy in 38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. "><b>Michalski 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.2 Gy in 44 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.67 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.19 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. "><b>Bruner 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy in 28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.00 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8 Gy in 41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.58 Gy</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>EQD<sub>2</sub>:</b> equivalent dose in 2 Gy fractions<br/><b>RT:</b> radiotherapy </p> </div> </div> <section id="CD012817-sec-0048"> <h4 class="title">Results of the search</h4> <p>We screened 12,469 records and removed 3727 duplicate publications. We screened the titles and abstracts of 8742 studies and excluded 8717 irrelevant publications. We examined 25 full‐text articles and excluded 15 studies that did not meet the inclusion criteria or were not relevant to the question under trial. One study is ongoing. This version of the review included nine studies (59 reports). The flow of literature through the assessment process is shown in the PRISMA flowchart (<a href="#CD012817-fig-0001">Figure 1</a>). </p> </section> <section id="CD012817-sec-0049"> <h4 class="title">Included studies</h4> <section id="CD012817-sec-0050"> <h5 class="title">Sources of data</h5> <p>We identified the nine published full‐text studies (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>). All trials were published in English. We attempted to contact three corresponding authors of included trials and reference trials to obtain additional information on study methods and results, and we received no or unhelpful responses. </p> </section> <section id="CD012817-sec-0051"> <h5 class="title">Study design and settings</h5> <p>All trials were single‐center or multicenter parallel randomized controlled trials that were conducted in various countries, such as the United Kingdom (<a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>), Netherlands (<a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>), France (<a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>), United States (<a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>), United Kingdom, New Zealand, Australia, Belgium (<a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>), Canada (<a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>), United States, Canada (<a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>), United States, Canada, and Switzerland (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>). <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>, <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>, <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>, <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>, <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>, <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>, and <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a> were reported as 'open‐label'. Two studies did not provide information regarding blinding (<a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>). The included studies were performed between the years 1993 and 2010. </p> </section> <section id="CD012817-sec-0052"> <h5 class="title">Participants</h5> <p>The nine studies included 5437 randomized participants (dose‐escalated RT 2723, conventional dose RT 2714). The mean age ranged from 66 to 71 years. Almost all men had localized prostate cancer (cT1‐3N0M0) except for 10. Ten men with cT4 were included in the <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a> study but were included as the number of cT4 patients was less than 1%. Most of the participants had a Gleason score of less than 8, and the proportion of patients with a Gleason score of 8 to 10 was approximately 5% (285 men). More than half of the participants had a pre‐treatment PSA of less than 10 ng/mL, but participants with higher than 20 ng/mL were also included. Median follow‐up ranged from 5.1 to 14.3 years (<a href="#CD012817-tbl-0003">Table 2</a>).  </p> </section> <section id="CD012817-sec-0053"> <h5 class="title">Interventions and comparators</h5> <p>In more than half of the studies, RT proceeded with 3DCRT rather than IMRT. Two studies (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>) reported image‐guided radiotherapy (IGRT) using fiducial markers and two studies (<a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>) reported some form of motion management. Three studies (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>) described normal quality assurance to evaluate delivered RT. In <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>, only the prostate was included in the RT volume, and in the remaining eight studies, the RT volume was the prostate and seminal vesicle. Five studies (<a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>) used androgen deprivation (<a href="#CD012817-tbl-0004">Table 3</a>). Most RT was performed with the conventional fraction, and mild hypofractions were used in the dose‐escalated group in two studies (<a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>). The EQD<sub>2</sub> range of dose‐escalated RT was 74 to 80 Gy, and conventional dose RT was 64 to 71 Gy (<a href="#CD012817-tbl-0005">Table 4</a>). </p> </section> <section id="CD012817-sec-0054"> <h5 class="title">Comparisons</h5> <p>All studies included RCTs comparing dose‐escalated RT to conventional dose RT (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>). </p> </section> <section id="CD012817-sec-0055"> <h5 class="title">Outcomes</h5> <p>We identified reporting of all primary and secondary outcomes in each of the included studies. All included studies reported oncologic outcomes. Six studies (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>) reported acute RT toxicity and eight (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>) reported late RT toxicity. <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a> reported quality of life using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire and <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a> using the self‐administered Short Form‐36 (SF‐36) questionnaire. </p> </section> <section id="CD012817-sec-0056"> <h5 class="title">Funding sources and conflicts of interest</h5> <p>All included studies reported funding sources. <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a> was supported by the Institute of Cancer Research (ICR), and Cancer Research UK (CRUK) Grant Number C46/A3970 to the ICR Section of Radiotherapy and C1491/A9895 to the ICR Clinical Trials and Statistics Unit. <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a> was supported by grants NKI 98‐1830 and CKTO 96‐10 from the Dutch Cancer Society. The <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a> was supported by grants from the Programme Hospitalier de Recherche Clinique (PHRC) and the Ligue Nationale Contre le Cancer. <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a> was supported in part by the Cancer Center Support Grant (National Cancer Institute Grant No. P30 CA016672). <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a> was supported in part by grants CA 06294 and CA 16672 from the National Cancer Institute, and US Department of Health and Human Services. <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a> was sponsored by UK Medical Research Council and conducted by the MRC Clinical Trials Unit (from August 2013, part of University College London). <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a> was supported by Pharmaceuticals Grant #DC‐990‐0049 from AstraZeneca Canada Inc. <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a> was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology Statistical and Data Management Center), U10CA37422 (Community Clinical Oncology Program), UG1CA189867 (NCI Community Oncology Research Program), U24CA180803 (Imaging and Radiation Oncology Core), and CA81647 Advanced Technology QA Center (ATC) from the National Cancer Institute. <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a> was supported by grants U10CA21661 (RTOG‐Ops‐Stat), U10CA37422 (CCOP), CA81647 (ATC), U10CA 180868 (NRG Oncology Operations), and U10CA180822 (NRG Oncology SDMC) from the National Cancer Institute (NCI). </p> </section> </section> <section id="CD012817-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We excluded 15 studies out of 25 studies after evaluating the full‐text publications. Three studies used the wrong study design (<a href="./references#CD012817-bbs2-0014" title="GoldnerG , BomboschV , BeckerG , WachterS , GlockerS , FeldmannH , et al. 10-year results of the prospective German-Austrian phase II multicenter study for risk-adapted radiotherapy of localized prostate cancer with a moderate dose escalation from 70 to 74 Gy. Strahlentherapie und Onkologie2014;190:37-8. ">Goldner 2014</a>; <a href="./references#CD012817-bbs2-0016" title="ISRCTN04483921. Dose escalation to intraprostatic tumour nodules in localised prostate cancer. www.isrctn.com/ISRCTN04483921 (first received 17 August 2011). ">ISRCTN04483921</a>; <a href="./references#CD012817-bbs2-0018" title="KubanD , PollackA , HuangE , LevyL , DongL , StarkschallG , et al. Hazards of dose escalation in prostate cancer radiotherapy. International Journal of Radiation Oncology Biology Physics2003;57(5):1260-8. ">Kuban 2003</a>). Each of three studies had the wrong intervention (<a href="./references#CD012817-bbs2-0012" title="ArnalotPF , MaldonadoX , BonetM , JoveJ , RovirosaA , RicoM , et al. Chemoradiotherapy in high-risk prostate cancer (QRT SOGUG trial): preliminary report. Radiotherapy and Oncology2016;119:157. ">Arnalot 2016</a>; <a href="./references#CD012817-bbs2-0020" title="NCT00936390. A phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer - RTOG 0815. clinicaltrials.gov/NCT00936390 (first received 10 July 2010). ">NCT00936390</a>; <a href="./references#CD012817-bbs2-0024" title="ZietmanAL , BaeK , SlaterJD , ShipleyWU , EfstathiouJA , CoenJJ , et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. Journal of Clinical Oncology2010;28:1106-11. [DOI: 10.1200/JCO.2009.25.8475]ZietmanAL , DeSilvioML , SlaterJD , RossiCJ , MillerDW , AdamsJA , et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA2005;294(10):1233-9. ">Zietman 2010</a>). Two studies had the wrong comparator (<a href="./references#CD012817-bbs2-0010" title="AlexidisP , DragoumisD , KaratzoglouS , DrevelegasK , TzitzikasI , HatzimouratidisK , et al. The role of hypofractionated radiotherapy for the definitive treatment of localized prostate cancer: early results of a randomized trial. Journal of Cancer2019;10(25):6217-24. ">Alexidis 2019</a>; <a href="./references#CD012817-bbs2-0011" title="AlexidisP , KaratzoglouS , DragoumisD , DrevelegasK , TzitzikasI , HatzimouratidisK , et al. Late results of a randomized trial on the role of mild hypofractionated radiotherapy for the treatment of localized prostate cancer. Journal of Cancer2020;11(5):1008-16. ">Alexidis 2020</a>). Seven studies reported the wrong type of publication, including letters to editors (<a href="./references#CD012817-bbs2-0013" title="DenhamJW . MRC RT01: an important trial. Lancet2007;8(6):459-60. ">Denham 2007</a>; <a href="./references#CD012817-bbs2-0015" title="GottschalkA . Commentary on “70 Gy vs 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial”. Urologic Oncology2012;30(3):347. ">Gottschalk 2012</a>; <a href="./references#CD012817-bbs2-0017" title="JeantrouxJ , FleschJ , NoélG . Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcima of the prostate. A randomized controlled trial. Cancer Radiotherapie2006;10(1-2):96-7. ">Jeantroux 2006</a>; <a href="./references#CD012817-bbs2-0019" title="MichalskiJM . Does dose escalation using conformal radiotherapy improve control of prostate cancer?Nature Clinical Practice Urology2005;2(7):322-3. ">Michalski 2005</a>; <a href="./references#CD012817-bbs2-0021" title="PughSL , LeeWR , DignamJ , LowD , SwansonGP , ShahAB , et al. NRG Oncology/RTOG 0415, hypofractionation in patients with low-risk prostate cancer: are patient reported outcomes the practice change tipping point?Quality of Life Research2017;26(1):38-9. ">Pugh 2017</a>; <a href="./references#CD012817-bbs2-0022" title="WielenGJ , PuttenWLJ , IncrocciL . Sexual functioning after conformal radiotherapy for prostate cancer: results of a dose-escalation study. Tijdschrift voor Urologie2008;16(1):16-21. ">Wielen 2008</a>; <a href="./references#CD012817-bbs2-0023" title="ZietmanAL , DeSilvioML , SlaterJD , RossiCJ , MillerDW , AdamsJA , et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA2008;299(8):899-900. ">Zietman 2008</a>). Further details of the excluded studies are presented elsewhere (see <a href="./references#CD012817-sec-0130" title="">Characteristics of excluded studies</a>). </p> <section id="CD012817-sec-0058"> <h5 class="title">Studies awaiting classification and ongoing trials</h5> <p>We found no studies awaiting classification. The <a href="./references#CD012817-bbs2-0025" title="NCT00967863. Radiation therapy in treating patients receiving hormone therapy for prostate cancer (GETUG-AFU 18). clinicaltrials.gov/NCT00967863 (first received 28 August 2009). ">GETUG‐AFU 18 trial</a> is ongoing. Details of these trials are presented elsewhere (see <a href="./references#CD012817-sec-0131" title="">Characteristics of ongoing studies</a>). </p> </section> </section> </section> <section id="CD012817-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>For details, refer to the <a href="./references#CD012817-sec-0129" title="">Characteristics of included studies</a>, Risk of bias summary (<a href="#CD012817-fig-0002">Figure 2</a>) for the main comparison. </p> <section id="CD012817-sec-0060"> <h4 class="title">Allocation</h4> <section id="CD012817-sec-0061"> <h5 class="title">Random sequence generation</h5> <p>We rated all studies as having a low risk of bias (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>). </p> </section> <section id="CD012817-sec-0062"> <h5 class="title">Allocation concealment</h5> <p>We rated three studies as having a low risk of bias (<a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>) and we rated the other studies as having an unclear risk of bias due to a lack of information on the allocation method. </p> </section> </section> <section id="CD012817-sec-0063"> <h4 class="title">Blinding</h4> <section id="CD012817-sec-0064"> <h5 class="title">Blinding of participants and personnel</h5> <p>We rated seven studies as having a high risk of bias due to being open‐label studies (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>), and we rated the remaining two studies as having an unclear risk of bias due to lack of information on blinding (<a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>). </p> </section> <section id="CD012817-sec-0065"> <h5 class="title">Blinding of outcome assessment</h5> <p>• Subjective outcomes (time to death from prostate cancer, RT toxicity, time to distant metastasis, quality of life): We rated seven studies as having a high risk of bias due to being open‐label studies (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>), and we rated the remaining two studies as having an unclear risk of bias due to lack of information on blinding (<a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>).<br/>• Objective outcomes (time to death from any cause, time to biochemical recurrence): we rated all studies as having a low risk of bias for these outcomes as they were unlikely to be affected by lack of blinding. </p> </section> </section> <section id="CD012817-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>• Oncologic survival outcomes (time to death from prostate cancer, time to death from any cause, time to distant metastasis, time to biochemical recurrence): we rated all studies as having a low risk of bias. </p> <p>• Acute RT toxicity: We rated four studies as having a low risk of bias (<a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>). The <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a> was rated as having an unclear risk of bias. We judged <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a> and <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a> as having a high risk of bias. We rated <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a> and <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a> as having an unclear risk of bias due to no or unusable report of acute RT toxicity. </p> <p>• Late RT toxicity: We rated seven studies as having a low risk of bias (<a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>; <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>). We judged <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a> and <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a> as having a high risk of bias. </p> <p>• Quality of life: We judged <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a> and <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a> as having an unclear and high risk of bias, respectively. We rated the remaining studies as having an unclear risk of bias due to no report on quality of life. </p> </section> <section id="CD012817-sec-0067"> <h4 class="title">Selective reporting</h4> <p>We rated four studies as having a low risk of bias (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>). We rated the remaining studies as having an unclear risk of bias given the lack of available protocols or reporting of study outcomes that were not predefined in the protocol. </p> </section> <section id="CD012817-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p>We rated all studies as having a low risk of bias; we identified no other sources of bias. </p> </section> </section> <section id="CD012817-sec-0069"> <h3 class="title" id="CD012817-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD012817-tbl-0001"><b>Summary of findings 1</b> Dose‐escalated RT compared to conventional dose RT for clinically localized and locally advanced prostate cancer</a> </p> <p>Details are presented elsewhere (see <a href="./full#CD012817-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD012817-sec-0070"> <h4 class="title">Primary outcomes</h4> <section id="CD012817-sec-0071"> <h5 class="title">1. Time to death from prostate cancer</h5> <p>Dose‐escalated RT probably results in little to no difference in time to death from prostate cancer (HR 0.83, 95% CI 0.66 to 1.04; I<sup>2</sup> = 0%; 8 studies; 5231 participants; median follow‐up 5.1 to 14.3 years; moderate‐certainty evidence). Assuming a risk of death from prostate cancer of 4 per 1000 in the conventional dose RT group, this corresponds to 1 fewer men per 1000 (1 fewer to 0 more) in the dose‐escalated RT group dying of prostate cancer. We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD012817-fig-0003" title="">Analysis 1.1</a>). </p> </section> <section id="CD012817-sec-0072"> <h5 class="title">2. Severe RT toxicity </h5> <p>Dose‐escalated RT probably results in little to no difference in severe RT toxicity. We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD012817-fig-0006" title="">Analysis 1.4</a>).  </p> <section id="CD012817-sec-0073"> <h6 class="title">GI toxicity</h6> <p> <ol id="CD012817-list-0018"> <li> <p>Acute: RR 0.68, 95% CI 0.39 to 1.16; I<sup>2</sup> = 0%; 6 studies; 3825 participants; moderate‐certainty evidence; 6 fewer men per 1000 (11 fewer to 3 more) in the dose‐escalated RT group assuming severe acute GI toxicity as 17 per 1000 in the conventional dose RT group. </p> </li> <li> <p>Late: RR 1.72, 95% CI 1.32 to 2.25; I<sup>2</sup> = 0%; 8 studies; 4992 participants; moderate‐certainty evidence; 23 more men per 1000 (10 more to 40 more) in the dose‐escalated RT group assuming severe late GI toxicity as 32 per 1000 in the conventional dose RT group. </p> </li> </ol> </p> </section> <section id="CD012817-sec-0074"> <h6 class="title">GU toxicity</h6> <p> <ol id="CD012817-list-0019"> <li> <p>Acute: RR 1.11, 95% CI 0.84 to 1.47; I<sup>2</sup> = 0%; 6 studies; 3825 participants; moderate‐certainty evidence; 5 more men per 1000 (7 fewer to 21 more) in the dose‐escalated RT group assuming severe acute GU toxicity as 44 per 1000 in the conventional dose RT group </p> </li> <li> <p>Late: RR 1.25, 95% CI 0.95 to 1.63; I<sup>2</sup> = 0%; 8 studies; 4962 participants; moderate‐certainty evidence: 9 more men per 1000 (2 fewer to 23 more) in the dose‐escalated RT group assuming severe late GU toxicity as 37 per 1000 in the conventional dose RT group. </p> </li> </ol> </p> </section> </section> </section> <section id="CD012817-sec-0075"> <h4 class="title">Secondary outcomes</h4> <section id="CD012817-sec-0076"> <h5 class="title">1. Time to death from any cause</h5> <p>Dose‐escalated RT probably results in little to no difference in time to death from any cause (HR 0.98, 95% CI 0.89 to 1.09; I<sup>2</sup> = 0%; 9 studies; 5437 participants; median follow‐up 5.1 to 14.3 years; moderate‐certainty evidence). Assuming a risk of death from any cause of 101 per 1000 in the conventional dose RT group at 10 years, this corresponds to 2 fewer men per 1000 (11 fewer to 9 more) in the dose‐escalated RT group dying from any cause. We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD012817-fig-0007" title="">Analysis 1.5</a>).  </p> </section> <section id="CD012817-sec-0077"> <h5 class="title">2. Time to distant metastasis</h5> <p>Dose‐escalated RT probably results in little to no difference in time to distant metastasis (HR 0.83, 95% CI 0.57 to 1.22; I<sup>2</sup> = 45%; 7 studies; 3499 participants; median follow‐up 5.1 to 14.3 years; moderate‐certainty evidence). Assuming a risk of distant metastasis of 29 per 1000 at 10 years in the conventional dose RT group, this corresponds to 5 fewer men per 1000 (12 fewer to 6 more) in the dose‐escalated RT group. We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD012817-fig-0011" title="">Analysis 1.9</a>). </p> </section> <section id="CD012817-sec-0078"> <h5 class="title">3. Overall RT toxicity </h5> <section id="CD012817-sec-0079"> <h6 class="title">GI toxicity:</h6> <p>While dose‐escalated RT probably results in little to no difference in acute GI toxicity, it may increase overall late GI toxicity. </p> <p> <ol id="CD012817-list-0020"> <li> <p>Acute: RR 1.03, 95% CI 0.96 to 1.10; I<sup>2</sup> = 0%; 5 studies; 3161 participants; moderate‐certainty evidence; 10 more men per 1000 (14 fewer to 35 more) in the dose‐escalated RT group assuming overall acute GI toxicity as 346 per 1000 in the conventional dose RT group. </p> </li> <li> <p>Late: RR 1.27, 95% CI 1.04 to 1.55; I<sup>2</sup> = 85%; 7 studies; 4328 participants; low‐certainty evidence; 92 more men per 1000 (14 more to 188 more) in the dose‐escalated RT group assuming overall late GI toxicity as 342 per 1000 in the conventional dose RT group. </p> </li> </ol> </p> </section> <section id="CD012817-sec-0080"> <h6 class="title">GU toxicity:</h6> <p>Dose‐escalated RT probably results or may result in little to no difference in overall GU toxicity. </p> <p> <ol id="CD012817-list-0021"> <li> <p>Acute: RR 1.01, 95% CI 0.95 to 1.06; I<sup>2</sup> = 0%; 5 studies; 3161 participants; moderate‐certainty evidence; 5 fewer men per 1000 (27 fewer to 32 more) in the dose‐escalated RT group assuming overall acute GU toxicity as 537 per 1000 in the conventional dose RT group. </p> </li> <li> <p>Late: RR 1.12, 95% CI 0.97 to 1.29; I<sup>2</sup> = 51%; 7 studies; 4298 participants; low‐certainty evidence; 34 more men per 1000 (9 fewer to 82 more) in the dose‐escalated RT group assuming overall late GU toxicity as 283 per 1000 in the conventional dose RT group. </p> </li> </ol> </p> <p>We rated the certainty of the evidence as moderate or low, downgrading for study limitations and/or imprecision (<a href="./references#CD012817-fig-0014" title="">Analysis 1.12</a>). </p> </section> </section> <section id="CD012817-sec-0081"> <h5 class="title">4. Quality of life</h5> <section id="CD012817-sec-0082"> <h6 class="title">Short term:</h6> <p>Dose‐escalated RT may result or probably results in little to no difference in quality of life using EPIC. </p> <p> <ol id="CD012817-list-0022"> <li> <p>Bowel function: MD ‐3.8, 95% CI ‐5.94 to ‐1.66; 1 study; 570 participants; low‐certainty evidence </p> </li> <li> <p>Urinary function: MD ‐1.5, 95% CI ‐3.44 to 0.44; 1 study; 577 participants; moderate‐certainty evidence </p> </li> <li> <p>Sexual function: MD ‐0.2, 95% CI ‐3.56 to 3.16; 1 study; 535 participants; moderate‐certainty evidence </p> </li> <li> <p>Hormonal function: MD 0, 95% CI ‐1.49 to 1.49; 1 study; 554 participants; moderate‐certainty evidence </p> </li> </ol> </p> </section> <section id="CD012817-sec-0083"> <h6 class="title">Long term:</h6> <p>Dose‐escalated RT may result or probably results in little to no difference in quality of life using SF‐36. </p> <p> <ol id="CD012817-list-0023"> <li> <p>Summary score physical health (SSPH): MD ‐3.9, 95% CI ‐12.78 to 4.98; 1 study; 300 participants; moderate‐certainty evidence </p> </li> <li> <p>Summary score mental health (SSMH): MD ‐3.6, 95% CI ‐83.85 to 76.65; 1 study; 300 participants; low‐certainty evidence </p> </li> </ol> </p> <p>We rated the certainty of the evidence as moderate or low, downgrading for study limitations and/or imprecision (<a href="./references#CD012817-fig-0015" title="">Analysis 1.13</a>). </p> </section> </section> <section id="CD012817-sec-0084"> <h5 class="title">5. Time to biochemical recurrence</h5> <p>Dose‐escalated RT probably extends time to biochemical recurrence (HR 0.68, 95% CI 0.61 to 0.75; I<sup>2</sup> = 0%; 9 studies; 5437 participants; median follow‐up 5.1 to 14.3 years; moderate‐certainty evidence). Assuming a risk of biochemical recurrence of 310 per 1000 in the conventional dose RT group, this corresponds to 87 fewer men per 1000 (107 fewer to 67 fewer) at 10 years in the dose‐escalated RT group developing distant metastases. We rated the certainty of the evidence as moderate, downgrading for study limitations (<a href="./references#CD012817-fig-0016" title="">Analysis 1.14</a>). </p> </section> </section> <section id="CD012817-sec-0085"> <h4 class="title">Subgroup analysis </h4> <section id="CD012817-sec-0086"> <h5 class="title">1. Time to death from prostate cancer</h5> <p>There was no evidence of a subgroup effect on time to death from prostate cancer with androgen deprivation therapy when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 1.31, P = 0.25, I<sup>2</sup> = 23.9%; <a href="./references#CD012817-fig-0004" title="">Analysis 1.2</a>). Time to death from prostate cancer without androgen deprivation therapy use had HR 0.65 (95% CI 0.44 to 0.96; I<sup>2</sup> = 0%; 4 studies; 3198 participants; median follow‐up 5.1 to 14.3 years) versus with androgen deprivation therapy use had HR 0.90 (95% CI 0.61 to 1.33; I<sup>2</sup> = 5%; 3 studies; 1369 participants; median follow‐up 10 to 13.7 years). </p> </section> <section id="CD012817-sec-0087"> <h5 class="title">2. Time to death from any cause</h5> <p>There was no evidence of a subgroup effect on time to death from any cause with androgen deprivation therapy when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 0.43, P = 0.51, I<sup>2</sup> = 0%; <a href="./references#CD012817-fig-0008" title="">Analysis 1.6</a>). Time to death from any cause without androgen deprivation therapy use had HR 1.02 (95% CI 0.89 to 1.17; I<sup>2</sup> = 0%; 4 studies; 3198 participants; median follow‐up 5.1 to 14.3 years) versus with androgen deprivation therapy use had HR 0.94 (95% CI 0.78 to 1.14; I<sup>2</sup> = 0%; 3 studies; 1369 participants; median follow‐up 10 to 13.7 years). </p> </section> <section id="CD012817-sec-0088"> <h5 class="title">3. Time to distant metastasis</h5> <p>There was no evidence of a subgroup effect on time to distant metastasis with androgen deprivation therapy when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 0.57, P = 0.45, I<sup>2</sup> = 0%; <a href="./references#CD012817-fig-0012" title="">Analysis 1.10</a>). Time to distant metastasis without androgen deprivation therapy use had HR 0.63 (95% CI 0.36 to 1.09; I<sup>2</sup> = 41%; 3 studies; 2106 participants; median follow‐up 5.1 to 14.3 years) versus with androgen deprivation therapy use had HR 0.85 (95% CI 0.48 to 1.50; I<sup>2</sup> = 0%; 2 studies; 526 participants; median follow‐up 11.3 to 13.7 years). </p> </section> <section id="CD012817-sec-0089"> <h5 class="title">4. Time to biochemical recurrence</h5> <p>There was no evidence of a subgroup effect on time to biochemical recurrence with androgen deprivation therapy when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 1.53, P = 0.22, I<sup>2</sup> = 34.5%; <a href="./references#CD012817-fig-0017" title="">Analysis 1.15</a>). Time to biochemical recurrence without androgen deprivation therapy use had HR 0.61 (95% CI 0.53 to 0.71; I<sup>2</sup> = 0%; 4 studies; 3198 participants; median follow‐up 5.1 to 14.3 years) versus with androgen deprivation therapy use had HR 0.71 (95% CI 0.60 to 0.85; I<sup>2</sup> = 0; 3 studies; 1369 participants; median follow‐up 10 to 13.7 years). </p> </section> <section id="CD012817-sec-0090"> <h5 class="title">Risk stratification</h5> <p>We were unable to conduct the preplanned subgroup analyses for time to death from prostate cancer and time to distant metastasis based on risk stratification due to a lack of data to analyze. </p> </section> <section id="CD012817-sec-0091"> <h5 class="title">1. Time to death from any cause</h5> <p>There was no evidence of a subgroup effect on time to death from any cause with risk stratification when the three subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 0.21, P = 0.90, I<sup>2</sup> = 0%; <a href="./references#CD012817-fig-0009" title="">Analysis 1.7</a>). Time to death from any cause for low risk participants had HR 0.92 (95% CI 0.64 to 1.32; I<sup>2</sup> = 0%; studies = 2; participants = 1252; median follow‐up 5.8 to 10 years; low‐certainty evidence), for intermediate risk had HR 1.00 (95% CI 0.86 to 1.16; I<sup>2</sup> = 0%; studies = 3; participants = 2210; median follow‐up 8.4 to 11.3 years), and for high risk had HR 0.95 (95% CI 0.68 to 1.33; I<sup>2</sup> = not applicable; studies = 1; participants = 362; median follow‐up 10 years). </p> </section> <section id="CD012817-sec-0092"> <h5 class="title">2. Time to biochemical recurrence</h5> <p>There was no evidence of a subgroup effect on biochemical recurrence with risk stratification when the three subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 0.77, P = 0.68, I<sup>2</sup> = 0%; <a href="./references#CD012817-fig-0018" title="">Analysis 1.16</a>). Biochemical recurrence for participants with low risk had HR 0.71 (95% CI 0.51 to 1.00; I<sup>2</sup> = 0%; studies = 2; participants = 1252; median follow‐up 5.8 to 10 years), for intermediate risk had HR 0.69 (95% CI 0.54 to 0.88; I<sup>2</sup> = 0%; studies = 3; participants = 2210; median follow‐up 8.4 to 11.3 years), and for high risk had HR 0.60 (95% CI 0.46 to 0.79; I<sup>2</sup> = not applicable; studies = 1; participants = 362; median follow‐up 10 years). </p> </section> <section id="CD012817-sec-0093"> <h5 class="title">1. Time to death from prostate cancer</h5> <p>There was no evidence of a subgroup effect on time to death from prostate cancer with fractionation of dose‐escalated radiotherapy when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 0.17, P = 0.68, I<sup>2</sup> = 0%; <a href="./references#CD012817-fig-0005" title="">Analysis 1.3</a>). Time to death from prostate cancer for conventional fraction had HR 0.83 (95% CI 0.65 to 1.05; I<sup>2</sup> = 6%; 7 studies; 4139 participants; median follow‐up 5.1 to 14.3 years) and for mild hypofraction had HR 0.51 (95% CI 0.05 to 5.03; I<sup>2</sup> = not applicable; 1 study; 1092 participants; median follow‐up 5.8 years). </p> </section> <section id="CD012817-sec-0094"> <h5 class="title">2. Time to death from any cause</h5> <p>There was no evidence of a subgroup effect on time to death from any cause with fractionation of dose‐escalated radiotherapy when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 0.37, P = 0.54, I<sup>2</sup> = 0%; <a href="./references#CD012817-fig-0010" title="">Analysis 1.8</a>). Time to death from any cause for conventional fraction had HR 0.99 (95% CI 0.89 to 1.11; I<sup>2</sup> = 0%; studies = 7; participants = 4139; median follow‐up 5.1 to 14.3 years) and for mild hypofraction had HR 0.89 (95% CI 0.64 to 1.24; I<sup>2</sup> = 0%; studies = 2; participants = 1298; median follow‐up 5.8 to 8.5 years). </p> </section> <section id="CD012817-sec-0095"> <h5 class="title">3. Time to distant metastasis</h5> <p>There was no evidence of a subgroup effect on time to distant metastasis with fractionation of dose‐escalated radiotherapy when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 1.17, P = 0.28, I<sup>2</sup> = 14.7%; <a href="./references#CD012817-fig-0013" title="">Analysis 1.11</a>). Time to distant metastasis for conventional fraction had HR 0.82 (95% CI 0.56 to 1.20; I<sup>2</sup> = 49%; 6 studies; 3293 participants; median follow‐up 5.1 to 14.3 years) and for mild hypofraction had HR 7.25 (95% CI 0.14 to 370.38; I<sup>2</sup> = not applicable; 1 study; 206 participants; median follow‐up 8.5 years). </p> </section> <section id="CD012817-sec-0096"> <h5 class="title">4. Time to biochemical recurrence</h5> <p>There was no evidence of a subgroup effect on time to biochemical recurrence with fractionation of dose‐escalated radiotherapy when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 0.07, P = 0.80, I<sup>2</sup> = 0%; <a href="./references#CD012817-fig-0019" title="">Analysis 1.17</a>). Time to biochemical recurrence for conventional fraction had HR 0.68 (95% CI 0.61 to 0.75; I<sup>2</sup> = 0%; 7 studies; 4139 participants; median follow‐up 5.1 to 14.3 years) and for mild hypofraction had HR 0.63 (95% CI 0.37 to 1.08; I<sup>2</sup> = 43; 2 studies; 1298 participants; median follow‐up 5.8 to 8.5 years). </p> </section> </section> <section id="CD012817-sec-0097"> <h4 class="title">Sensitivity analysis</h4> <p>We were unable to conduct the preplanned sensitivity analyses by excluding studies at high or unclear risk of bias as all included studies were rated as unclear or high risk of bias. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012817-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012817-sec-0098"></div> <section id="CD012817-sec-0099"> <h3 class="title" id="CD012817-sec-0099">Summary of main results</h3> <p>The nine studies included 5437 randomized participants. Mean age ranged from 67 to 71 years. Almost all men had localized prostate cancer (cT1‐3N0M0). Most of the patients had a Gleason score of 8 or less, and more than two‐thirds had a PSA of 10 or less. Compared to conventional dose RT, dose‐escalated RT appears to have a similar effect on time to death from prostate cancer, severe RT toxicity, time to death from any cause, overall RT toxicity (except for late GI toxicity), quality of life, and time to distant metastasis. Dose‐escalated RT may increase overall late GI toxicity. Dose‐escalated RT probably decreases the time to biochemical recurrence rate. There was no evidence of a subgroup effect on oncologic survival outcomes with androgen deprivation therapy, risk stratification, and fractionation of dose‐escalated radiotherapy. </p> </section> <section id="CD012817-sec-0100"> <h3 class="title" id="CD012817-sec-0100">Overall completeness and applicability of evidence</h3> <p>The studies included in this review have important limitations.</p> <p> <ul id="CD012817-list-0024"> <li> <p>Given the relatively low mortality of prostate cancer and the extended time most patients live with the disease and any treatment sequelae, quality of life is a very important outcome measure. However, only two studies (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>) reported quality of life outcomes.  </p> </li> <li> <p>RT toxicity of surrounding tissues increases as the RT dose increases. Nevertheless, current RT techniques such as IMRT and IGRT have made remarkable progress and can significantly reduce RT toxicity. When dose‐escalated RT was performed with 3DCRT compared to IMRT, the rate of acute GI toxicity of grade 2 or higher was more than three times (20% vs 61%, P = 0.001) (<a href="./references#CD012817-bbs2-0027" title="Al-MamganiA , HeemsbergenWD , PeetersSTH , LebesqueJV . Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2009;73(3):685-91.">Al‐Mamgani 2009</a>). In only two studies, highly conformal RT, equivalent to the IMRT technique with image guidance, was applied (<a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>; <a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]">Hoffman 2018</a>). Most of the participants in the remaining studies were treated using 3DCRT (see <a href="#CD012817-tbl-0004">Table 3</a>). Therefore, the evidence for toxicity may not reflect modern RT techniques. </p> </li> <li> <p>The studies included a mixture of men with low‐, intermediate‐ and high‐risk diseases, except for <a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. ">Bruner 2019</a>, <a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. ">Michalski 2018</a>, and <a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]">Nabid 2021</a>. Of the remaining RCTs, only <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a> was analyzed according to risk stratification. The effectiveness of RT may be different for patients in each risk group. We reported time to death from any cause and time to biochemical recurrence by risk subgroup, but this was based on limited data. </p> </li> <li> <p>Biochemical recurrence after first‐line treatment of clinically localized and locally advanced prostate cancer does not always lead to clinically progressive disease (<a href="./references#CD012817-bbs2-0033" title="Van den BroeckT , Van den BerghRCN , BriersE , CornfordP , CumberbatchM , TilkiD , et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel Recommendations. European Urology Focus2020;6(2):231-4.">Broeck 2020</a>). In men who experience biochemical recurrence after primary treatment, a sufficiently long life expectancy is required for biochemical recurrence to affect mortality (<a href="./references#CD012817-bbs2-0067" title="PollackA , HanlonAL , MovsasB , HanksGE , UzzoR , HorwitzEM . Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. International Journal of Radiation Oncology Biology Physics2003;57(1):19-23.">Pollack 2003</a>). Since prostate cancer occurs more frequently in elderly patients, biochemical recurrence itself may have little effect on mortality. However, patients with biochemical recurrence may receive additional treatment such as androgen deprivation therapy, which may affect their quality of life. The potential benefits and toxicities of salvage treatment should be discussed with each patient considering both the European Association of Urology biochemical recurrence risk stratification and life expectancy (<a href="./references#CD012817-bbs2-0033" title="Van den BroeckT , Van den BerghRCN , BriersE , CornfordP , CumberbatchM , TilkiD , et al. Biochemical recurrence in prostate cancer: the European Association of Urology Prostate Cancer Guidelines Panel Recommendations. European Urology Focus2020;6(2):231-4.">Broeck 2020</a>). </p> </li> <li> <p>The included studies reported toxicity outcomes according to the organs that are commonly affected by RT such as GI and GU toxicity. Therefore, we could not derive the summarized results regarding the review outcome due to a unit of analysis error. </p> </li> <li> <p>Between 2011 and 2015, the incidences of prostate cancer in the United States were approximately 109 per 100,000 for all men, 102 for whites, 179 for blacks, 92 for Hispanics, and 56 for Asians (<a href="./references#CD012817-bbs2-0075" title="SiegelRL , MillerKD , JemalA . Cancer statistics, 2019. Cancer Journal for Clinicians2019;69(1):7-34.">Siegel 2019</a>). However, most of the patients included in the study were white. The anticipated absolute effect may vary depending on the incidence or prevalence. Therefore, it should be considered when applying to other races.  </p> </li> </ul> </p> </section> <section id="CD012817-sec-0101"> <h3 class="title" id="CD012817-sec-0101">Quality of the evidence</h3> <p>The certainty of the evidence rating on a per‐outcome basis ranged from moderate to low, indicating that we downgraded each outcome at least once. </p> <p> <ul id="CD012817-list-0025"> <li> <p>Study limitations: we downgraded for unclear risk of selection bias and high risk of blinding of participants, personnel, and outcome assessors. </p> </li> <li> <p>Imprecision: confidence intervals were wide and crossed the assumed threshold of a clinically important difference. </p> </li> </ul> </p> </section> <section id="CD012817-sec-0102"> <h3 class="title" id="CD012817-sec-0102">Potential biases in the review process</h3> <p>Despite a comprehensive search strategy with no publication or language restrictions, we may have missed additional RCTs that may be unpublished and/or were published in languages other than English. The small number of studies included in this review was insufficient to generate funnel plots; therefore, the risk of publication bias may have been underestimated. </p> <p>Where hazard ratios were not provided in the journal publications, we approximated hazard ratios using the statistical method (<a href="./references#CD012817-bbs2-0066" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17:2815-34.">Parmar 1998</a>; <a href="./references#CD012817-bbs2-0080" title="WilliamsonP , Tudur SmithC , HuttonJL , MarsonA . Aggregrate data meta-analysis with time-to-event outcomes. Statistics in Medicine2002;21:3337-51.">Williamson 2002</a>). This method can only reconstruct hazard ratios according to the information available and may have resulted in bias.  </p> </section> <section id="CD012817-sec-0103"> <h3 class="title" id="CD012817-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>We found two systematic reviews addressing the topic.</p> <p><a href="./references#CD012817-bbs2-0077" title="VianiGA , StefanoEJ , AfonsoSL . Higher than conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. International Journal of Radiation Oncology Biology Physics2009;74(5):1405.">Viani 2009</a> (search date 1996 to 2007) represents the first meta‐analysis that focused on dose‐escalated RT for prostate cancer. It included seven RCTs (<a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>; <a href="./references#CD012817-bbs2-0072" title="SathyaJR , DavisIR , JulianJA , GuoQ , DayaD , DayeIS , et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. Journal of Clinical Oncology2005;23(6):1192-9.">Sathya 2005</a>; <a href="./references#CD012817-bbs2-0074" title="ShipleyWU , VerheyLJ , MunzenriderJE , SuitHD , UrieMM , McManusPL , et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. International Journal of Radiation Oncology Biology Physics1995;32(1):3-12.">Shipley 1995</a>; <a href="./references#CD012817-bbs2-0024" title="ZietmanAL , BaeK , SlaterJD , ShipleyWU , EfstathiouJA , CoenJJ , et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. Journal of Clinical Oncology2010;28:1106-11. [DOI: 10.1200/JCO.2009.25.8475]ZietmanAL , DeSilvioML , SlaterJD , RossiCJ , MillerDW , AdamsJA , et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA2005;294(10):1233-9. ">Zietman 2010</a>). The authors included proton therapy and brachytherapy as interventions (<a href="./references#CD012817-bbs2-0072" title="SathyaJR , DavisIR , JulianJA , GuoQ , DayaD , DayeIS , et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. Journal of Clinical Oncology2005;23(6):1192-9.">Sathya 2005</a>; <a href="./references#CD012817-bbs2-0074" title="ShipleyWU , VerheyLJ , MunzenriderJE , SuitHD , UrieMM , McManusPL , et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. International Journal of Radiation Oncology Biology Physics1995;32(1):3-12.">Shipley 1995</a>; <a href="./references#CD012817-bbs2-0024" title="ZietmanAL , BaeK , SlaterJD , ShipleyWU , EfstathiouJA , CoenJJ , et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. Journal of Clinical Oncology2010;28:1106-11. [DOI: 10.1200/JCO.2009.25.8475]ZietmanAL , DeSilvioML , SlaterJD , RossiCJ , MillerDW , AdamsJA , et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA2005;294(10):1233-9. ">Zietman 2010</a>). Four other RCTs were included in our study but given the latest search date of 2007, they provided short‐term follow‐up results only. They reported that dose‐escalated RT significantly reduced the biochemical failure rate without benefits for specific prostate cancer mortality rates. There were more cases of grade ≥ 2 late GI toxicity after dose‐escalation RT, whereas GU toxicity did not increase significantly.  </p> <p><a href="./references#CD012817-bbs2-0055" title="HouZ , LiG , BaiS . High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta‑analysis of long-term follow-up. Journal of Cancer Research and Clinical Oncology2015;141:1063-71. [DOI: 10.1007/s00432-014-1813-1]">Hou 2015</a> (search date 1946 to 2014) is the most recent systematic review that also provides long‐term results. It included six RCTs (<a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. ">Creak 2013</a>; <a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. ">Dearnaley 2014</a>; <a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]">GETUG 06 trial</a>; <a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]">Heemsbergen 2014</a>; <a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]">Pasalic 2019</a>; <a href="./references#CD012817-bbs2-0024" title="ZietmanAL , BaeK , SlaterJD , ShipleyWU , EfstathiouJA , CoenJJ , et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. Journal of Clinical Oncology2010;28:1106-11. [DOI: 10.1200/JCO.2009.25.8475]ZietmanAL , DeSilvioML , SlaterJD , RossiCJ , MillerDW , AdamsJA , et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA2005;294(10):1233-9. ">Zietman 2010</a>). It also included the study with proton therapy (<a href="./references#CD012817-bbs2-0024" title="ZietmanAL , BaeK , SlaterJD , ShipleyWU , EfstathiouJA , CoenJJ , et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. Journal of Clinical Oncology2010;28:1106-11. [DOI: 10.1200/JCO.2009.25.8475]ZietmanAL , DeSilvioML , SlaterJD , RossiCJ , MillerDW , AdamsJA , et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA2005;294(10):1233-9. ">Zietman 2010</a>). It reported similar results to <a href="./references#CD012817-bbs2-0077" title="VianiGA , StefanoEJ , AfonsoSL . Higher than conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. International Journal of Radiation Oncology Biology Physics2009;74(5):1405.">Viani 2009</a> except for higher rates of grade ≥ 2 late GU toxicity after dose‐escalation RT.  </p> <p>Compared to the previously published reviews, our study included mild hypo‐fractionation regimens that are being widely used in routine clinical practice. In addition, we used a rigorous methodology that meets Cochrane standards including a comprehensive search and GRADE approach. MCIDs were used to assess the certainty of evidence regarding the effect estimates of the intervention. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012817-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Prisma flow diagram" data-id="CD012817-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Prisma flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias judgments for individual included studies" data-id="CD012817-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias judgments for individual included studies</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 1: Time to death from prostate cancer" data-id="CD012817-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 1: Time to death from prostate cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 2: Time to death from prostate cancer_subgroup analysis (without ADT vs with ADT)" data-id="CD012817-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 2: Time to death from prostate cancer_subgroup analysis (without ADT vs with ADT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 3: Time to death from prostate cancer_subgroup analysis (conventional fraction vs mild hypofraction)" data-id="CD012817-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 3: Time to death from prostate cancer_subgroup analysis (conventional fraction vs mild hypofraction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 4: Severe RT toxicity" data-id="CD012817-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 4: Severe RT toxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 5: Time to death from any cause" data-id="CD012817-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 5: Time to death from any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 6: Time to death from any cause_subgroup analysis (without ADT vs with ADT)" data-id="CD012817-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 6: Time to death from any cause_subgroup analysis (without ADT vs with ADT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 7: Time to death from any cause_subgroup analysis (low vs intermediate vs high risk)" data-id="CD012817-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 7: Time to death from any cause_subgroup analysis (low vs intermediate vs high risk) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 8: Time to death from any cause_subgroup analysis (conventional fraction vs mild hypofraction)" data-id="CD012817-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 8: Time to death from any cause_subgroup analysis (conventional fraction vs mild hypofraction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 9: Time to distant metastasis" data-id="CD012817-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 9: Time to distant metastasis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 10: Time to distant metastasis_subgroup analysis (without ADT vs with ADT)" data-id="CD012817-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 10: Time to distant metastasis_subgroup analysis (without ADT vs with ADT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 11: Time to distant metastasis_subgroup analysis (conventional fraction vs mild hypofraction)" data-id="CD012817-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 11: Time to distant metastasis_subgroup analysis (conventional fraction vs mild hypofraction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 12: Overall RT toxicity" data-id="CD012817-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 12: Overall RT toxicity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 13: Quality of life" data-id="CD012817-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 13: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 14: Time to biochemical recurrence" data-id="CD012817-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 14: Time to biochemical recurrence </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 15: Time to biochemical recurrence_subgroup analysis (without ADT vs with ADT)" data-id="CD012817-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 15: Time to biochemical recurrence_subgroup analysis (without ADT vs with ADT) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 16: Time to biochemical recurrence_subgroup analysis (low vs intermediate vs high risk)" data-id="CD012817-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 16: Time to biochemical recurrence_subgroup analysis (low vs intermediate vs high risk) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012817-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/urn:x-wiley:14651858:media:CD012817:CD012817-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 17: Time to biochemical recurrence_subgroup analysis (conventional fraction vs mild hypofraction)" data-id="CD012817-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_t/tCD012817-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Dose‐escalated RT versus conventional  dose RT, Outcome 17: Time to biochemical recurrence_subgroup analysis (conventional fraction vs mild hypofraction) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/media/CDSR/CD012817/image_n/nCD012817-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012817-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dose‐escalated RT compared to conventional dose RT for clinically localized and locally advanced prostate cancer</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Dose‐escalated RT compared to conventional dose RT for clinically localized and locally advanced prostate cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> clinically localized and locally advanced prostate cancer <br/><b>Setting:  </b> likely outpatients<br/><b>Intervention:</b> dose‐escalated RT <br/><b>Comparison:</b> conventional dose RT </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="2" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No of participants<br/>(studies)<br/>Follow up</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>What happens?</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with conventional dose RT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk difference with dose‐escalated RT</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><b>Time to death from prostate cancer</b> </p> <p>Follow‐up: assumed baseline risk at 10 years</p> <p> </p> <p>MCID: 3% absolute difference</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5231<br/>(8 RCTs<sup>1</sup>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.83</b><br/>(0.66 to 1.04) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Assumed baseline risk<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in time to death from prostate cancer. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 fewer per 1000<br/>(1 fewer to 0 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Severe RT toxicity </b> </p> <p><b>(grade ≥ 3)</b> </p> <p> </p> <p>Follow‐up: 5.1 to 8.7 years (median)</p> <p> </p> <p>MCID: 5% absolute difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late GI toxicity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4992<br/>(8 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.72</b><br/>(1.32 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in severe late RT toxicity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 more per 1000<br/>(10 more to 40 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late GU toxicity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4962<br/>(8 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.25</b><br/>(0.95 to 1.63) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/>(2 fewer to 23 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><b>Time to death from any cause</b> </p> <p>Follow‐up: assumed baseline risk at 10 years</p> <p> </p> <p>MCID: 3% absolute difference</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>5437<br/>(9 RCTs<sup>1</sup>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.98</b><br/>(0.89 to 1.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Assumed baseline risk<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in time to death from any cause. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 fewer per 1000<br/>(11 fewer to 9 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign="top"> <p><b>Time to distant metastasis</b> </p> <p>Follow‐up: assumed baseline risk at 10 years</p> <p> </p> <p>MCID: 3% absolute difference</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3499<br/>(7 RCTs<sup>1</sup>) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 0.83</b><br/>(0.57 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Assumed baseline risk<sup>3</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in time to distant metastasis.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 fewer per 1000<br/>(12 fewer to 6 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p><b>Overall RT toxicity </b> </p> <p><b>(grade ≥ 1)</b> </p> <p> </p> <p>Follow‐up: 5.1 to 8.7 years (median)</p> <p> </p> <p>MCID: 5% absolute difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late GI toxicity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4328<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>LOW<sup>2, 4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.27</b><br/>(1.04 to 1.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT may increase overall late GI toxicity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>342 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92 more per 1000<br/>(14 more to 188 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Late GU toxicity</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4298<br/>(7 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>LOW<sup>2, 4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.12</b><br/>(0.97 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Dose‐escalated RT may result in little to no difference in overall late GU toxicity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>283 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 more per 1000<br/>(9 fewer to 82 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Quality of life</b> </p> <p> </p> <p>Follow‐up: 36 months (long term)</p> <p> </p> <p>MCID: 25% relative difference<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SF‐36 (SSPH)<br/>Scale from 0 (worst) to 100 (best) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>300<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/><b>MODERATE<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The change from the baseline of SF‐36 was ‐4.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 3.9 lower<br/>(12.78 lower to 4.98 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose‐escalated RT probably results in little to no difference in quality of life (physical health). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SF‐36 (SSMH)</p> <p>Scale from 0 (worst) to 100 (best)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>300<br/>(1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>LOW<sup>2, 4</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The change from the baseline of SF‐36 was 0.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD 3.6 lower<br/>(83.85 lower to 76.65 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose‐escalated RT may result in little to no difference in quality of life (mental health). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> confidence interval; <b>GI:</b> gastrointestinal; <b>GU:</b> genitourinary; <b>HR:</b> hazard ratio; <b>MCID:</b> minimal clinically important difference; <b>MD:</b> mean difference; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy; <b>SF‐36</b> : self‐administered short form‐36 quality of life questionnaire; <b>SSMH</b> : summary score mental health; <b>SSPH</b>: summary score physical health </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>1</sup> Median follow‐up range of the included studies was 5.1 to 14.3 years. </p> <p><sup>2</sup> Downgraded by one level for study limitations: unclear or high risk of bias for one or more domains among the included studies </p> <p><sup>3</sup> Estimates for control event rates for survival rate come from  <a href="./references#CD012817-bbs2-0045" title="HamdyFC , DonovanJL , LaneJA , MasonM , MetcalfeC , HoldingP , et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine2016;375:1415-24.">Hamdy 2016</a>. </p> <p><sup>4</sup> Downgraded by one level for imprecision: confidence interval crosses the assumed threshold of clinically important difference </p> <p><sup>5</sup> Estimates for MCID as 25% relative difference (20 points) from the baseline (approximately 80 points) (<a href="./references#CD012817-bbs2-0044" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision [GRADE leitlinien: 6. Einschätzung der qualität der evidenz — unzureichende präzision]. Journal of Clinical Epidemiology2012;106:677-88.">Guyatt 2012</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Dose‐escalated RT compared to conventional dose RT for clinically localized and locally advanced prostate cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012817-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prostate cancer risk stratification</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Low risk</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gleason score &lt; 6, PSA &lt;10 ng/mL and clinical stage T1‐T2a</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intermediate risk</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gleason score 7, PSA 10‐20 ng/mL or clinical stage T2b</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>High risk</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gleason score 8‐10, PSA &gt; 20ng/mL or clinical stage &gt;T2c</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><b>PSA:</b> prostate‐specific antigen </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Prostate cancer risk stratification</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012817-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial period [year to year]/</b> </p> <p><b>duration of<br/>follow‐up</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study design/<br/>setting/<br/>country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Description of participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention and comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>No participants<br/>per arm/</b> </p> <p><b>age (years)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Clinical stage (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Gleason score (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>PSA (n)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk stratification</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. "><b>Creak 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1995 to 1997/13.7 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/single center/United Kingdom</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Histologically proven T1b‐T3b N0 M0 adenocarcinoma of the prostate. There was no limit on pre‐treatment PSA levels, and any histological grade was accepted. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 74 Gy in 37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62/</p> <p>median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (26%) cT2 (56%) cT3 (18%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 (18%) 2 (68%) 3 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median 14 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 20%</p> <p>Intermediate: 27%</p> <p>High: 53%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 64 Gy in 32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64/</p> <p>median 66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (17%) cT2 (44%) cT3 (39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 (19%) 2 (77%) 3 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median 15 ng/mL</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]"><b>Heemsbergen 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1997 to 2003/</p> <p>110 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>4 centers/</p> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Histologically proven cT1a‐T4 adenocarcinoma of the prostate with an initial PSA level of &lt; 60 mg/L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 78 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>333/</p> <p>mean 68.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (70)</p> <p>cT2 (137)</p> <p>cT3 (123) </p> <p>cT4 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐6 (170)</p> <p>7 (116)</p> <p>8‐10 (47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐10 (137)</p> <p>10‐20 (126)</p> <p>20‐60 (70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 17.3%</p> <p>Intermediate: 26.8%</p> <p>High: 50.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 68 Gy in 34 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>331/</p> <p>mean 68.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (59)</p> <p>cT2 (149)</p> <p>cT3 (116)</p> <p>cT4 (7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐6 (162)</p> <p>7 (113)</p> <p>8‐10 (56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐10 (119)</p> <p>10‐20 (126)</p> <p>20‐60 (86)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]"><b>GETUG 06 trial</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1999 to 2002/</p> <p>61 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>17 centers/</p> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>&lt; 75 years, life expectancy &gt; 10 years with low Charlson score ≤ 2, T1 tumors were eligible if the Gleason score was at least VII or if the PSA level was at least 10 ng/mL, T2 and T3a, baseline PSA &lt; 50 ng/dL. Node dissection performed when the risk of positive nodes &gt; 10% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 80 Gy in 40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153/</p> <p>mean 66.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (28)</p> <p>cT2 (105)</p> <p>cT3 (20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7 (96)</p> <p>7 (47)</p> <p>8 (10)</p> <p>9 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (56)</p> <p>10‐20 (71)</p> <p>&gt; 20 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Intermediate: 71.5%</p> <p>High: 28.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153/</p> <p>mean 67.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (35)</p> <p>cT2 (100)</p> <p>cT3 (18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 7 (96)</p> <p>7 (46)</p> <p>8 (10)</p> <p>9 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (62)</p> <p>10‐20 (67)</p> <p>&gt; 20 (24)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]"><b>Hoffman 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2001 to 2010/</p> <p>8.5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>single‐center/</p> <p>United States</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Biopsy‐confirmed prostate adenocarcinoma, good performance status (Zubrod &lt; 2), cT1b‐T3b (AJCC 4th), PSA ≤ 20 ng/mL, Gleason score &lt; 10, and no clinical, radiographic, or pathologic evidence of nodal or bone metastasis. Men with cT3 disease were required to have a Gleason score &lt; 8 and pretreatment PSA ≤ 10 ng/mL. Men with Gleason score 8 or 9 diseases were required to have cT1/T2 disease and pretreatment PSA ≤ 10 ng/mL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 72 Gy in 30 fraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104/</p> <p>median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (71)</p> <p>cT2 (33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (33)</p> <p>7 (70)</p> <p>8 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 10 (95)</p> <p>10.1‐20 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 27.7%</p> <p>Intermediate: 71.3%</p> <p>High: 1.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 75.6 Gy in 42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102/</p> <p>median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (77)</p> <p>cT2 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (37)</p> <p>7 (64)</p> <p>8 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 10 (91)</p> <p>10.1‐20 (11)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]"><b>Pasalic 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1993 to 1998/</p> <p>14.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>single‐center/</p> <p>United States</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>cT1‐T3N0M0 (AJCC 1992), MD Anderson pathology review, pretreatment PSA ≤ 30 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 78 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151/</p> <p>median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (43)</p> <p>cT2 (74)</p> <p>cT3 (34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6 (15)</p> <p>6 (59)</p> <p>7 (50)</p> <p>8 (22)</p> <p>9 (5)</p> <p>10 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (98)</p> <p>10‐20 (47)</p> <p>&gt; 20 (6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 20.6%</p> <p>Intermediate: 45.8%</p> <p>High: 33.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150/</p> <p>median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (45)</p> <p>cT2 (79)</p> <p>cT3 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6 (13)</p> <p>6 (57)</p> <p>7 (54)</p> <p>8 (19)</p> <p>9 (5)</p> <p>10 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (98)</p> <p>10‐20 (42)</p> <p>&gt; 20 (10)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. "><b>Dearnaley 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1998 to 2001/10 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/multicenter/United Kingdom, New Zealand, Australia, Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men 18 years or older with histologically confirmed T1b–T3a, N0, M0 prostate cancer and prostate‐specific antigen (PSA) of less than 50 ng/mL. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 74 Gy in 37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>422/</p> <p>median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (103) cT2 (239) cT3 (76) unknown (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 6 (249) 7 (117) </p> <p>≥ 8 (54) unknown (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean 15.2 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low: 19%</p> <p>Intermediate: 36%</p> <p>High: 44%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 64 Gy in 32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>421/</p> <p>median 67 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (106) cT2 (236) cT3 (71) unknown (8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≤ 6 (261) 7 (105) </p> <p>≥ 8 (52) unknown (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean 15.6 ng/mL<br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low: 19%</p> <p>Intermediate: 38%</p> <p>High: 43%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]"><b>Nabid 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2000 to 2010/</p> <p>11.3 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>11 centers/</p> <p>Canada</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Histologically proven intermediate‐risk prostate cancer, Zubrod performance scale 0‐1, age 80 years, and no evidence of regional or metastatic disease </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 76 Gy in 38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200/</p> <p>median 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (95)</p> <p>cT2 (105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2)</p> <p>6 (45)</p> <p>7 (153)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐4.9 (33)</p> <p>5‐9.9 (68)</p> <p>10‐20 (99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Intermediate: 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200/</p> <p>median 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (99)</p> <p>cT2 (101)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2)</p> <p>6 (53)</p> <p>7 (145)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0‐4.9 (25)</p> <p>5‐9.9 (54)</p> <p>10‐20 (121)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. "><b>Michalski 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2002 to 2008/8.4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/104 centers/Canada and US</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men with histologically confirmed prostate cancer diagnosed within 180 days of study randomization, a Zubrod performance scale of 0 to 1, clinical stage T1b to T2b with either a Gleason score of 2 to 6 and a PSA of at least 10 and less than 20 ng/mL (1:1 conversion to micrograms per liter) or Gleason score of 7 and a PSA of less than 15 ng/mL were eligible. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 79.2 Gy in 44 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>748/</p> <p>mean 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (423) cT2 (325)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐6 (126)</p> <p>7 (622)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (517) 10‐15 (187) 15‐20 (44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Intermediate: 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 70.2 Gy in 39 fractions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>751/</p> <p>mean 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (430) cT2 (321)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐6 (116)</p> <p>7 (635)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 10 (525) 10‐15 (195) 15‐20 (31)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. "><b>Bruner 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2006 to 2009/</p> <p>5.8 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RCT/</p> <p>multi‐center/</p> <p>United States, Canada, and Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Men age &gt; 18 years, Zubrod performance scale &lt; 2, low‐risk prostate cancer (cT1b‐T2cN0M0 AJCC 6th, Gleason score 2–6 and PSA &lt; 10 ng/mL) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I: 70 Gy in 28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>550/</p> <p>median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (442)</p> <p>cT2 (108)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐4 (0)</p> <p>5‐6 (550)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4 (112)</p> <p>4‐10 (438)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Low: 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C: 73.8 Gy in 41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542/</p> <p>median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cT1 (411)</p> <p>cT2 (131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐4 (2)</p> <p>5‐6 (540)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 4 (106)</p> <p>4‐10 (436)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p><b>AJCC:</b> American Joint Committee on Cancer<br/><b>C</b> : comparator<br/><b>I</b> : intervention<br/><b>n:</b> number of participants<br/><b>PSA:</b> prostate‐specific antigen (ng/mL)<br/><b>RCT:</b> randomized controlled trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012817-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Description of interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Technique</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Image‐guided RT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Motion control</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>RT QA</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>RT volume</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>CTV to PTV margins</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Androgen deprivation</b> <br/><b>(in both study  arms)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. "><b>Creak 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>± seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>either a 1 or 1.5 cm uniform margin </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]"><b>Heemsbergen 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 94%</p> <p>IMRT 6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comfortably full bladder and without specific immobilization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>± seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5–10 mm margin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]"><b>GETUG 06 trial</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orthogonal images</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Empty bladder and rectum 1 hour before the daily treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Central QA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>+ seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 mm all dimensions except 5 mm posteriorly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nil</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]"><b>Hoffman 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>step‐and‐shoot IMRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fiducial markers or<br/>ultrasound </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>+ seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10–15 mm all dimensions except 4–8 mm posteriorly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]"><b>Pasalic 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CT scan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>+ seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25‐1.5 cm in the antero‐inferior dimension and 0.75‐1.0 cm in the posterosuperior dimension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nil</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. "><b>Dearnaley 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>± seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0 cm margin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]"><b>Nabid 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate<br/>+ seminal<br/>vesicles </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10–15 mm all dimensions except 5–10 mm posteriorly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. "><b>Michalski 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 66.2% IMRT 33.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality control system compliant with National Cancer Institute guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>prostate + proximal 1 cm of seminal vesicle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5‐1.0 cm margin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nil</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. "><b>Bruner 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3DCRT 21%</p> <p>IMRT 79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>fiducial markers,<br/>ultrasound, or<br/>cone‐beam CT </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Central QA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4–10 mm margin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nil</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>CT:</b> computed tomography<br/><b>CTV:</b> clinical target volume<br/><b>IMRT:</b> intensity‐modulated radiation therapy<br/><b>NR:</b> not reported<br/><b>PTV:</b> planning target volume<br/><b>RT:</b> radiotherapy<br/><b>QA:</b> quality assurance<br/><b>3DCRT:</b> three‐dimensional conformal radiation therapy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Description of interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012817-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Equivalent dose in 2 Gy fractions of included studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study name</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose‐escalated RT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose per fraction</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>EQD<sub>2</sub> (α/β = 1.5)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Conventional RT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Dose per fraction</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>EQD<sub>2</sub> (α/β = 1.5)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0002" title="CreakA , HallE , HorwichA , EelesR , KhooV , HuddartR , et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. British Journal of Cancer2013;109:651-7. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:488-98. "><b>Creak 2013</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy in 37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy in 32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0005" title="Al-MamganiA , HeemsbergenWD , LevendagPC , LebesqueJV . Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial. Radiotherapy and Oncology2010;96:13-8. [DOI: 10.1016/j.radonc.2010.02.022]Al-MamganiA , PuttenWLJ , HeemsbergenWD , LeendersGJLH , SlotA , DielwartMFH , et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics2008;72(4):980–8. [DOI: 10.1016/j.ijrobp.2008.02.073]Al-MamganiA , PuttenWLJ , WielenGJ , LevendagPC , IncrocciL . Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). International Journal of Radiation Oncology Biology Physics2011;79(4):1004-12. [DOI: 10.1016/j.ijrobp.2009.12.039]HeemsbergenWD , Al-MamganiA , SlotA , DielwartMFH , LebesqueJV . Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival. Radiotherapy and Oncology2014;110:104-9. [DOI: 10.1016/j.radonc.2013.09.026]HeemsbergenWD , HoogemanMS , WitteMG , PeetersSTH , IncrocciL , LebesqueJV . Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 Gy versus 78 Gy. International Journal of Radiation Oncology Biology Physics2007;67(5):1418–24. [DOI: 10.1016/j.ijrobp.2006.11.014]HeemsbergenWD , PeetersSTH , KoperPCM , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology Biology Physics2006;66(1):3-10. [DOI: 10.1016/j.ijrobp.2006.03.055]PeetersSTH , HeemsbergenWD , KoperPCM , PuttenWLJ , SlotA , DielwartMFH , et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology2006;24(13):1990-6. [DOI: 10.1200/JCO.2005.05.2530]PeetersSTH , HeemsbergenWD , PuttenWLJ , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. International Journal of Radiation Oncology Biology Physics2005;61(4):1019-34. [DOI: 10.1016/j.ijrobp.2004.07.715]PeetersSTH , LebesqueJV , HeemsbergenWD , PuttenWLJ , SlotA , DielwartMFH , et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics2006;64(4):1151–61. [DOI: 10.1016/j.ijrobp.2005.10.002]"><b>Heemsbergen 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68 Gy in 34 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0004" title="BeckendorfV , GuérifS , PriséEL , CossetJM , BougnouxA , ChauvetB , et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. International Journal of Radiation Oncology Biology Physics2011;80(4):1056-63. [DOI: 10.1016/j.ijrobp.2010.03.049]BeckendorfV , GuérifS , PriséEL , CossetJM , LeflochO , ChauvetB , et al. The GETUG 70 Gy vs 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. International Journal of Radiation Oncology Biology Physics2004;60(4):1056-65. [DOI: 10.1016/j.ijrobp.2004.05.033]"><b>GETUG 06 trial</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 Gy in 40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy in 35 fractions </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0006" title="HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. American Journal of Clinical Oncology2018;41(6):558–67. [DOI: 10.1097/COC.0000000000000325]HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose-escalated, intensity-modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943-9. [DOI: 10.1200/JCO.2018.77.9868]HoffmanKE , VoongKR , PughTJ , SkinnerH , LevyLB , TakiarV , et al. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity-modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics2014;88(5):1074-84. [DOI: 10.1016/j.ijrobp.2014.01.015]"><b>Hoffman 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 Gy in 30 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.23Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.6 Gy in 42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.28Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0009" title="KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?International Journal of Radiation Oncology Biology Physics2011;79(5):1310-7. [DOI: 10.1016/j.ijrobp.2010.01.006]KubanDA , TuckerSL , DongL , StarkschallG , HuangEH , CheungMR , et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. International Journal of Radiation Oncology Biology Physics2008;70(1):67-74. [DOI: 10.1016/j.ijrobp.2007.06.054]LittleDJ , KubanDA , LevyLB , ZagarsGK , PollackA . Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology2003;62:707–13. [DOI: 10.1016/s0090-4295(03)00504-1]NguyenLN , PollackA , ZagarsGK . Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology1998;51:991–7. [DOI: 10.1016/s0090-4295(98)00028-4]PasalicD , KubanDA , AllenPK , TangC , MeskoSM , GrantSR , et al. Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial. International Journal of Radiation Oncology Biology Physics2019;104(4):790-7. [DOI: 10.1016/j.ijrobp.2019.02.045]PollackA , ZagarsGK , SmithLG , LeeJJ , EschenbachAC , AntolakJA , et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. Journal of Clinical Oncology2000;18(23):3904-11. [DOI: 10.1200/JCO.2000.18.23.3904]PollackA , ZagarsGK , StarkschallG , AntolakJA , LeeJJ , HuangE , et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics2002;53(5):1097-105. [DOI: 10.1016/s0360-3016(02)02829-8]StoreyMR , PollackA , ZagarsGK , SmithLG , AntolakJA , RosenI , et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. International Journal of Radiation Oncology Biology Physics2000;48(3):635–42. [DOI: 10.1016/s0360-3016(00)00700-8]"><b>Pasalic 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0003" title="BarnettGC , MeerleerG , GullifordSL , SydesMR , ElliottRM , DearnaleyDP . The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clinical Oncology2011;23:613-24. DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet2014;15:464-73. DearnaleyDP , SydesMR , LangleyRE , GrahamJD ,  HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiotherapy and Oncology2007;83:31-41. DearnaleyDP , SydesRM , GrahamJD , AirdEG , BottomleyD , CowanRA , et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet2007;8:475-87. SydesMR , StephensRJ , MooreAR , AirdEG , BidmeadAM , FallowfieldLJ , et al. Implementing the UK medical research council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiotherapy and Oncology2004;42:199-211. SyndikusI , MorganRC , SydesMR , GrahamJD , DearnaleyDP , MRC RT01 collaborators. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). International Journal of Radiation Oncology Biology Physics2010;77(3):773-83. "><b>Dearnaley 2014</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy in 37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy in 32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0008" title="NabidA , CarrierN , Vigneault E, NguyenTV , Vavassis P, BrassardMA , et al. Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial. European Journal of Cancer2021;143:64-74. [DOI: 10.1016/j.ejca.2020.10.023]"><b>Nabid 2021</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 Gy in 38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy in 35 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0007" title="BrunerDW , HuntD , MichalskiJM , BoschWR , GalvinJM , AminM , et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer2015;121:2422-30. DelouyaG , KaufmanG , SylvestreMP , NguyenTV , BaharyJP , TausskyD , et al. The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer. Cancer Epidemiology2012;36:137-41. MichalskiJM , MoughanJ , PurdyJ , BoschW , BrunerDW , BaharyJP , et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer the NRG Oncology RTOG 0126 randomized clinical trial. JAMA2018;4(6):e180039. "><b>Michalski 2018</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.2 Gy in 44 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.67 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2 Gy in 39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.19 Gy</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD012817-bbs2-0001" title="BrunerDW , PughSL , LeeWR , HallWA , DignamJJ , LowD , et al. Quality of life in patients with low-risk prostate cancer treated with hypofractionated vs conventional radiotherapy: a phase 3 randomized clinical trial. JAMA2019;5(5):664-70. LeeWR , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325-32. "><b>Bruner 2019</b> </a> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy in 28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.00 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8 Gy in 41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.58 Gy</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>EQD<sub>2</sub>:</b> equivalent dose in 2 Gy fractions<br/><b>RT:</b> radiotherapy </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Equivalent dose in 2 Gy fractions of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/full#CD012817-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012817-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dose‐escalated RT versus conventional  dose RT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Time to death from prostate cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.66, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Time to death from prostate cancer_subgroup analysis (without ADT vs with ADT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.60, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 without ADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 with ADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.61, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Time to death from prostate cancer_subgroup analysis (conventional fraction vs mild hypofraction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.66, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 conventional fraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.65, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 mild hypofraction </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1092</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.05, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Severe RT toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Severe acute GI toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.39, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Severe late GI toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.32, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Severe acute GU toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.84, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Severe late GU toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.95, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Time to death from any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Time to death from any cause_subgroup analysis (without ADT vs with ADT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 without ADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 with ADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Time to death from any cause_subgroup analysis (low vs intermediate vs high risk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.64, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Intermediate risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.86, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.68, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Time to death from any cause_subgroup analysis (conventional fraction vs mild hypofraction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 conventional fraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 mild hypofraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.64, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Time to distant metastasis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.57, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Time to distant metastasis_subgroup analysis (without ADT vs with ADT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.50, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 without ADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.36, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 with ADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.48, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Time to distant metastasis_subgroup analysis (conventional fraction vs mild hypofraction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.57, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 conventional fraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.56, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 mild hypofraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.25 [0.14, 370.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Overall RT toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 Overall acute GI toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.96, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 Overall late GI toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.04, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 Overall acute GU toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.4 Overall late GU toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.97, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 EPIC, bowel (B‐12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐5.94, ‐1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 EPIC, urinary (B‐12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐3.44, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 EPIC, sexual (B‐12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>535</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐3.56, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.4 EPIC, hormonal (B‐12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.49, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.5 SF‐36, SSPH (B‐36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐12.78, 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.6 SF‐36, SSMH (B‐36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐83.85, 76.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Time to biochemical recurrence <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.61, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Time to biochemical recurrence_subgroup analysis (without ADT vs with ADT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.58, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 without ADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.53, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 with ADT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.60, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Time to biochemical recurrence_subgroup analysis (low vs intermediate vs high risk) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3824</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.57, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.51, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Intermediate risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.54, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.46, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Time to biochemical recurrence_subgroup analysis (conventional fraction vs mild hypofraction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.61, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.1 conventional fraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.61, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.17.2 mild hypofraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.37, 1.08]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Dose‐escalated RT versus conventional  dose RT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012817.pub2/references#CD012817-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012817.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012817-note-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012817-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012817-note-0029">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012817-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012817-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="id#CD012817-note-0030">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD012817-note-0013">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012817-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD012817-note-0031">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD012817-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012817-note-0027">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012817-note-0023">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012817-note-0025">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012817\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012817\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012817\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012817\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012817\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012817.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012817.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012817.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012817.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012817.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728584041"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012817.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728584045"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012817.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec8049840f431',t:'MTc0MDcyODU4NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 